COMbination of Bipolar Androgen Therapy and Nivolumab in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase: PHASE2
Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

COMbination of Bipolar Androgen Therapy and Nivolumab in Patients with Metastatic 
Castration-Resistant Prostate Cancer
Principal Investigator: Mark C. Markowski, M.D., PhD
NCT03554317
Protocol Version 8.9, Date: June 9, 2021

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
1 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients 
with Metastatic Castration‐Resistant Prostate Cancer  
[COMBAT‐CRPC] 
 
PCCTC LOI #: c18-219 
BMS Protocol #: CA209-8CE 
IND #: IND 138431 
Lead Site and Sponsor: Johns Hopkins University 
 
Principal Investigator 
Mark C. Markowski, M.D., Ph.D. 
Prostate Cancer Program 
The Skip Viragh Outpatient Cancer Building 
Johns Hopkins University 
201 N. Broadway, Room 9160, Mailbox 7  
Baltimore, MD 21287 
Tel 410-614-0567 
Fax 410-367-2668 
Email: mmarko12@jhmi.edu  
 
 
 
Co‐Principal investigator 
Emmanuel S. Antonarakis, M.D. 
Prostate Cancer Program 
The Skip Viragh Outpatient Cancer Building 
Johns Hopkins University 
201 N. Broadway, Room 9129, Mailbox 7                    
Baltimore, MD 21287 
Tel 410-502-7528 
Fax 410-367-2668 
Email: eantona1@jhmi.edu  
 
 
Statistician 
Hao Wang, Ph.D. 
Wei Fu, MS 
Division of Biostatistics & Bioinformatics 
Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins  
Johns Hopkins University, School of Medicine 
Baltimore, MD, USA 
Tel 410-614-3426 
Tel 410-955-4884 
Email: hwang76@jhmi.edu; wfu@jhu.edu  
 
 
Lead Study Pathologist 
Angelo De Marzo M.D., Ph.D. 
Department of Pathology 
Johns Hopkins University,  
School of Medicine 
1650 Orleans Street 
CRB2, Room 144 
Baltimore, MD 21231 
Tel 410-614-5686 
Email: ademarz@jhmi.edu   
 
 
Project Manager 
Aliya Lalji 
The Skip Viragh Outpatient Cancer Building 
Johns Hopkins University 
201 N. Broadway, Mailbox 7 
Baltimore, MD 21287 
Tel 410-502-5101 
Fax 410-367-2668 
Email: alalji1@jhmi.edu  

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
2 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
 
 
 
 
 
 
 
 
 
Protocol Version 8.0  Protocol Date: June 9, 2021 
CONFIDENTIALITY STATEMENT 
The information in this document is provided to you as an investigator, potential investigator, 
consultant, or contractor, for review by you, your staff, and the appropriate Institutional Review 
Board or Ethics Committee. By accepting this document, you agree that the information 
contained herein will not be disclosed to others without written authorization from the lead 
site/sponsor, except to the extent necessary to initiate the study or conduct study-related 
activities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
3 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
INVESTIGATOR APPROVAL OF PROTOCOL 
 
COMbination of Bipolar Androgen Therapy and Nivolumab in Patients with 
Metastatic Castration‐Resistant Prostate Cancer  
[COMBAT‐CRPC] 
 
 
Protocol Version: 
 
 
 
V. 8.0 
Version Date:   
 
 
 
6/9/2021 
 
 
 
Principal Investigator Signature:  
_______________________________________________________ 
Principal Investigator Name:  
_______________________________________________________ 
Date of Signature:  
 
 
_______________________________________________________ 
 
 
 
 
 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
4 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
SYNOPSIS 
Title 
COMbination of Bipolar Androgen Therapy and Nivolumab in Men with Metastatic 
Castration-Resistant Prostate Cancer [COMBAT-CRPC] 
Lead site 
Johns Hopkins University 
Sponsor 
IND holder 
Bristol-Myers Squibb 
Mark C. Markowski, MD, Ph.D 
Investigational 
agent 
Testosterone Cypionate 400mg IM every 28 days; Nivolumab 480mg IV every 4 weeks 
Phase 
2 
Target 
population 
 
Adult male > 18 years of age 
 
Histologic or cytologic diagnosis of adenocarcinoma of the prostate. 
 
Known castration-resistant disease, defined according to PCWG3 
 
Metastatic disease as defined for ≥ 1 bone metastases confirmed by bone 
scintigraphy or radiographic soft tissue metastasis. Pelvic lymph nodes will be 
considered as metastatic disease if they measure > 15 mm in short-axis diameter. 
 
Soft tissue lesion available for biopsy collection. 
 
PSA and/or radiographic progression on at least ONE prior second generation AR-
targeted therapies (i.e. abiraterone acetate, enzalutamide); and up to ONE prior 
chemotherapy agent for mCRPC is permitted. 
 
Serum PSA at screening > 2.0 ng/mL 
 
Serum testosterone level < 50 ng/dL at time of screening 
 
Life expectancy ≥ 6 months 
 
ECOG performance status  < 2 
 
Adequate bone marrow, renal and liver function (ANC > 1.0K, Plt > 100K, Hgb ≥ 9 
g/dL; CrCl ≥ 40 mL/min; AST/ALT WNL; Total Bilirubin WNL). 
 
Study centers 
 
Two participating sites in the United States, parts of the PCCTC network. 
Start 
date/Duration 
First patients are expected to be enrolled in Q3/Q4 2018. Accrual is estimated to last 
18 months with up to 24 months of follow-up after the last patient has been entered. 
Expected 
enrollment 
44 patients 
Rationale 
Rationale for Combination of High-Dose Testosterone with Nivolumab in Metastatic 
Castration Resistant Prostate Cancer (mCRPC) Patients 
 
Bipolar Androgen Therapy (BAT) alone: BAT is a paradoxical approach for the 
treatment of mCRPC whereby testosterone levels are rapidly cycled between 
supraphysiologic and near-castrate concentrations. Based on prior studies, the 
incidence of germline mutations in DNA-repair genes in mCRPC patients is ~12% with 
somatic DNA-repair mutations approaching 20-25%.  Interestingly, we have identified 
a correlation between long-term (“exceptional”) responders to BAT and the presence 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
5 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
of mutations in homologous-recombination DNA repair genes.  In Teply et al. (Eur Urol, 
2017), we report the case of a patient with mCRPC who achieved a durable (>24 mo) 
complete radiographic and serologic response following treatment with BAT.  DNA 
sequencing found inactivating mutations in both BRCA2 and ATM, which were 
confirmed on germline DNA testing.  We are currently sequencing tumor/germline 
DNA from other “exceptional” responders to BAT, and remarkably, we have found DNA 
repair mutations in 5/6 extreme responders.  These unpublished findings suggest a 
relationship between responses to BAT and the presence of mutations in DNA-repair 
genes.   
    
Checkpoint Blockade alone: Two randomized phase III trials involving single-agent 
checkpoint (CTLA-4) inhibitors in mCRPC patients did not meet their primary 
endpoints.  However, a small subset (~20%) of mCRPC patients did derive clinical 
benefit.  In pilot studies conducted at Johns Hopkins, we have observed dramatic 
responses to checkpoint inhibition in those patients with DNA-repair defects.  For 
instance, two patients (#1: MSH6-mutated; #2: BRCA2-mutated) achieved a PSA50 
response following combined PD-1/CTLA-4 checkpoint inhibition.  A third mCRPC 
patient (#3: ATM-mutated) achieved a partial radiographic RECIST response.  A fourth 
patient (#4: POLH-mutated) also had a RECIST response.  Similar to the efficacy of 
checkpoint inhibitors in patients with MSI-High colon cancer, we speculate that a 
benefit of immunotherapy may be observed in those mCRPC patients with germline 
and/or somatic mutations in DNA-repair genes.  
 
BAT/Immunotherapy Combination: Even more notably, we have observed two mCRPC 
patients with intact DNA repair processes (i.e. no repair gene mutations) that were 
treated initially with BAT and subsequently achieved dramatic PSA/RECIST responses 
to PD-1 checkpoint inhibition.  Patient #1 achieved a PSA50 response to BAT which 
lasted 11 months before developing subsequent PSA progression.  Upon starting 
nivolumab in combination with an anti-CD73 inhibitor, his PSA level dropped from 692 
ng/mL to 3 ng/mL in the first 12 weeks with an associated clinical benefit.  Patient #2 
also achieved a PSA50 response to BAT lasting 6 months.  Following subsequent 
treatment with checkpoint inhibition, his PSA dropped from 56 ng/mL to 4 ng/mL with 
a partial radiographic response after only 3 months of therapy. As mentioned, neither 
patients had a DNA-repair mutation although both benefited dramatically from PD-1 
inhibition. Further study of BAT with nivolumab is warranted. 
Objectives 
Primary: 
To estimate the PSA50 response rate, defined as a > 50% decline in PSA from baseline, 
confirmed with a second measurement at least 4 weeks apart (PCWG3). 
Secondary: 
 
To estimate the median PSA progression-free survival (PSA-PFS)(PCWG3). 
 
To estimate the median progression-free survival (PFS)(PCWG3). 
 
To estimate the durable progression-free survival (PFS > 6 months) 
 
To estimate the objective response rate (ORR) 
 
To estimate median overall survival (OS) 
 
To determine the safety and tolerability of BAT/Nivolumab in the mCRPC 
population. 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
6 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Correlatives/Tertiary: 
 
To estimate the percentage of patients with somatic (tumor) or germline 
(inherited) mutations in homologous repair (HR) and/or mismatch repair 
genes. 
 
To measure IHC-based changes in gamma-H2AX, RAD51, 53BP1 (DNA damage 
markers) following treatment with BAT and at progression on BAT/nivolumab. 
 
To measure changes in CD4, CD8, FOXP3, Ki-67, PD-1, PD-L1 tumor levels with 
BAT alone and at progression following BAT/Nivolumab. 
 
To investigate any association between PD-1 and PD-L1 expression in tumor 
specimens and PSA50 response rates. 
 
To explore the relationship between mutation-associated neoantigen (MANA) 
and tumor-associated neoantigen (TAA) assays and clinical outcomes. 
 
To characterize the effect of BAT on production of inflammatory chemokines 
and cytokines. 
 
Study design 
The study is an open-label, single arm, Phase II trial. Eligible patients are men with 
mCRPC.  All patients must have a rising PSA and/or radiographic progression and prior 
treatment with at least one novel AR targeted therapy (i.e. abiraterone acetate, 
enzalutamide), and up to one prior chemotherapy agent for mCRPC is permitted. A 
mandatory tumor biopsy will be performed prior to the start of therapy in all patients. 
A second, mandatory tumor biopsy will take place after three months of therapy with 
BAT alone.  A third, OPTIONAL biopsy will be performed following PSA and/or 
radiographic progression on BAT/Nivolumab. 
After enrollment, patients will be treated with testosterone cypionate 400mg IM every 
4 weeks for a lead-in period of 12 weeks.  Patients will be followed monthly with clinic 
visits, safety labs (including CBC w/ Diff, CMP), PSA, and toxicity assessments.  After 
the lead-in period, all patients will be treated with nivolumab 480mg IV every 4 weeks 
and maintained on testosterone cypionate 400mg IM every 4 weeks.  Treatment [with 
a minimum drug exposure of 12 weeks] will be continued until PSA progression 
(PCGW3 criteria) or clinical/radiographic progression (whichever comes first), or until 
unmanageable toxicity requiring drug cessation.  Patients will continue a GnRH 
analogue during the study or have undergone orchiectomy. 
 
 
 
 
 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
7 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
The trial schema:  
 
 
Criteria for 
evaluation 
Primary Endpoint 
 
PSA50 response rate, defined as a ≥ 50% decline in PSA from baseline, confirmed 
with a second measurement at least 4 weeks later (PCWG3).  
Secondary Endpoints 
 
Safety/Tolerability, defined as incidence of CTCAE Grade ≥ 3 toxicities 
experienced by patients on the trial. 
 
PSA progression-free survival (PSA-PFS), defined as the time from initiation on 
testosterone therapy until PSA increase of 25%, confirmed with another 
measurement at least 4 weeks later (PCWG3). 
 
Progression–free survival (PFS)(PCWG3), defined as the time to radiographic or 
clinical progression or death, whichever comes first. Based on RECIST version 
1.1 and PCWG3 definitions including: Progression of soft tissue lesions according 
to RECIST 1.1; Progression of bone lesions detected with bone scan according to 
PCWG3 criteria; Radiologically-confirmed spinal cord compression or 
pathological fracture due to malignant progression, or other clinical event 
deemed to be cancer-related. 
 
Objective response rate (ORR), defined as the proportion of patients achieving a 
complete/partial response in target lesions (RECIST 1.1). 
 
Durable Progression-free survival (Durable PFS), defined as a lack of 
clinical/radiographic progression for > 6 months. 
 
Median Overall Survival (OS), defined as the time from study enrollment to 
death from any cause up to 2 years after the last dose of study treatment 
received. 
 
Testosterone Lead‐in 
Testosterone + Nivolumab 
Testosterone 400mg IM q4wks 
Nivolumab 480mg IV q4wks 
T 
T 
T 
Nivo 
PSA 
CT C/A/P 
Bone Scan 
 
PSA  
CT C/A/P 
Bone Scan 
 
PSA 
 
Con nue  
un l  
Progression 
or 
Toxicity 
(Biopsy at progression) 
biopsy 
biopsy 
PSA 
 
12 weeks 
12 weeks 
T 
PSA 
 
T 
Nivo 
PSA 
 
T 
Nivo 
T 
Nivo 
PSA  
CT C/A/P 
Bone Scan 
 
C1D1 
C2D1 
C3D1 
C4D1 
C5D1 
C6D1 
C7D1 
Cycle Length: 28 days 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
8 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Exploratory Endpoints 
 
PSA50 response, in patients with and without a somatic or germline HR or MMR  
gene mutation. 
 
To associate PSA response to BAT/Nivolumab with changes in gamma-H2AX, 
RAD51, 53BP1 formation in tumor tissue compared to baseline. 
 
To associate PSA50 response to BAT/Nivolumab with changes in CD4, CD8, 
FOXP3, PD-1, PD-L1 levels in tumor tissue compared to baseline. 
 
To associate clinical responses to BAT +/- Nivolumab with the generation of 
mutation-associated neoantigens. (MANAs) or tumor-associated neoantigens 
(TAAs). 
 
To characterize the effect of BAT on production of inflammatory chemokines 
and cytokines. 
 
Exploratory Analyses 
 
Estimate the Percentage of Patients with a Pathogenic Somatic or Germline Mutation in a 
HR or MMR Gene Mutations: 
The somatic DNA mutations present in the tumor will be identified through Foundation 
Medicine sequencing.  Germline DNA mutation testing per standard of care practice will 
be done using clinical-grade testing in a CLIA-certified laboratory prior to the start of 
treatment for consenting subjects only. Patients with a germline and/or somatic 
deleterious alteration in the pre-specified gene list (BRCA1, BRCA2, ATM, CHEK2, NBN, 
RAD50, RAD51C, RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, 
FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 and 
PMS2) will be considered biomarker positive. For biomarker positive and biomarker 
negative subjects, we will calculate PSA50 response rates with confidence intervals for 
hypothesis generation.   
  
PD‐1, PD‐L1, FOXP3, CD4, CD8, γH2AX, RAD51, 53BP1 Protein Levels:  
Subjects will have pretreatment, on-treatment (and at progression) tumor biopsy 
specimens analyzed.  IHC staining for PD-1 and PD-L1 will be performed on the 
pretreatment samples and scored as <1%, 1-5%, 5-10%, >10% and the results will be 
associated with responses for both proteins, separately, using descriptive statistics and 
Fisher’s Exact Tests.   Immunofluorescence will be used to quantify the median intensity 
of each gamma-H2AX, RAD51 and 53BP1 foci per cell as well as determine the median 
number of foci per cell on the pretreatment biopsies.  Using analytical microscopy, Drs. 
Meeker and Heaphy have developed imaging software, which can isolate single nuclei 
and quantify both the intensity and number of immunofluorescent foci per nucleus (i.e. 
per cell). Using FFPE tissue obtained at biopsy, we will examine the change in DNA 
damage foci number and intensity (reported as median percent change) induced by 
BAT/Nivolumab in PSA50 responders versus non-responders using a T-test.  Using 
imaging software, we will count the number of CD4+ and CD8+ lymphocytes in pre-
treatment and on-treatment biopsies. We will correlate PSA50 responses with CD4+ and 
CD8+ lymphocyte tumor infiltration. 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
9 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Interrogate for Mutation‐associated Neoantigens (MANAs) and Tumor‐associated 
Neoantigens (TAAs): 
Whole-exome sequencing will be performed on pre-treatment samples, after 12 weeks 
of BAT lead-in therapy, and post-progression tumor and matched normal samples. 
Exome data will be applied in a neoantigen prediction pipeline that evaluates antigen 
processing, MHC binding, and gene expression to generate neoantigens specific to the 
patient’s HLA haplotype. Truncal neoantigens will be identified by correcting for tumor 
purity and ploidy. Putative-neoantigens will then be used to generate peptides and 
stimulate autologous T cells, followed by TCR next-generation sequencing. 
 
To Characterize the Effect of BAT on Production of Inflammatory Chemokines and 
Cytokines:   
Milliplex human cytokine/chemokine Immunology Multiplex Assay (Millipore-Sigma) 
will be used to assay acute effects of BAT on production of cytokines and chemokines.  
Plasma samples are obtained at screening, 3 hours after the first testosterone injection, 
3 days after the first testosterone injection, Cycle 2 Day 1, and Cycle 7 Day 1. Analysis 
will be performed by the Immune Processing Core Lab at Johns Hopkins. 
 
Statistical 
method 
Primary Analysis 
The primary endpoint of this study is PSA50 response, defined as a decrease in the PSA to 
≥ 50% less than the baseline PSA upon enrollment in the trial. The decrease must be 
confirmed by a second measurement at least 4 weeks apart. For purposes of meeting the 
primary endpoint, patients will be considered to have done so if they have a PSA50 
response either while on therapy with BAT alone (during lead-in) or BAT in 
combination with Nivolumab (combination phase).  PSA values will be measured 
monthly during the trial.  All patients who take at least one dose of BAT (during lead-in) 
will be considered evaluable for the primary endpoint. If patients do not have at least 
one follow-up PSA after initiation of BAT due to stopping therapy for toxicity or 
withdrawing consent, then they will be replaced. PSA50 response rate will be estimated 
along with 95% confidence interval. 
 
Secondary Analysis 
Safety: 
Patients will be assessed for toxicities at each clinical evaluation. Toxicities will graded 
according to current CTCAE standardized grading scales.  The incidence of grade 3-5 
toxicities will be reported to the lead site and to BMS. Patients will be assessed for 
toxicity as long as they are taking BAT alone or BAT in combination with Nivolumab, 
and patients will continue to be followed if treatment is discontinued for toxicity until 
the toxicities improve to grade 1 or resolve. Toxicities will be reported as a tabulated 
table by type and grade. 
 
PSA Progression‐free Survival (PSA‐PFS): 
A standard definition of PSA progression per PCWG3 will be used. PSA-PFS will be 
defined as an increase in 25% over a nadir value, confirmed by a follow-up PSA at least 4 
weeks later. If patients are removed from the study prior to PSA progression, then they 
will be censored at that time.  We will use the Kaplan-Meier method to summarize the 
median PSA-PFS. 
 
Progression‐free Survival (PFS): 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
10 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Progression-free survival will be measured from the time of the first dose to objective 
clinical or radiographic tumor progression as defined by PCWG3 for progressive disease 
or death, and summarized using a Kaplan-Meier curve. Progression will be assigned to 
the earliest observed time. Patients whose disease has not progressed at follow-up will 
be censored at the date when the last tumor assessment determined a lack of 
progression.  We will use the Kaplan-Meier method to summarize the median PFS. 
 
Objective Response Rate (ORR): 
The objective response rate is defined as the percentage of patients who achieve an 
objective response by RECIST 1.1 criteria (i.e. Complete response or Partial Response) 
to BAT alone or BAT in combination with Nivolumab. We will estimate the objective 
response rate, along with the exact 95% confidence interval, for the population of 
patients with RECIST-evaluable disease.   
Durable Progression‐free Survival (durable‐PFS): 
Durable PFS will be defined as the proportion of patients without clinical or 
radiographic progression, as defined by PCWG3, or death for at least 24 weeks from the 
start of treatment. 
Overall Survival (OS): 
Overall survival will be defined as the time from study enrollment to death from any 
cause up to 2 years after the last dose of study treatment.  This will be summarized 
using a Kaplan-Meier curve. 
 
Sample Size/Power Calculation: 
The sample size is calculated to detect an improved PSA50 response rate from 25% (null 
hypothesis) to 45% (alternative). A minimax Simon two stage design is planned. A total 
of 23 patients will be entered in the first stage. A planned analysis will be performed 12 
weeks after the last patient in the first stage receives the first dose of nivolumab.  If ≤ 5 
subjects have a PSA50 response, the study will be terminated and we will conclude the 
regimen is ineffective (i.e. not more effective than BAT alone). If ≥ 6 subjects respond in 
the first stage, then an additional 16 patients will be enrolled, for a total of 39 patients.  
If a total of ≤ 13 subjects respond in stage one and two combined, we consider this 
regimen ineffective. If a total of ≥ 14 respond, we will conclude that the regimen is 
promising and warrants further study. A total of 44 patients will be enrolled to account 
for a 10% possible dropout rate and unevaluable patients.  
 
This design provides 90% power to detect an absolute 20% increase in PSA response 
rate with a one-sided type I error of 0.1. The chance of early stopping for futility is 0.49 
if PSA50 response rate is 25%. 
 
Safety analysis Standard safety summaries will be provided for treatment exposure, patient disposition, 
adverse events leading to discontinuation, serious adverse events, and all events 
resulting in death, including those up to 100 days after treatment discontinuation. The 
incidence of adverse events will be tabulated and reviewed for potential significance 
and clinical importance. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
11 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
TABLE OF CONTENTS 
1. INTRODUCTION .............................................................................................................................................................. 13 
1.1 
Disease Background .......................................................................................................................................................... 13 
1.2 
Treatment Background .................................................................................................................................................... 14 
1.3 
Rationale ................................................................................................................................................................................. 24 
2.1 
Primary Objective ............................................................................................................................................................... 28 
2.2 
Secondary Objectives ........................................................................................................................................................ 28 
2.3 
Correlative/Exploratory/Tertiary Objectives ....................................................................................................... 28 
3. 
PATIENT SELECTION ............................................................................................................................................. 29 
3.1 
Target Population ............................................................................................................................................................... 29 
3.2 
Expected Enrollment ......................................................................................................................................................... 29 
3.3 
Inclusion Criteria ................................................................................................................................................................ 29 
3.4 
Exclusion Criteria ............................................................................................................................................................... 30 
4. 
PATIENT REGISTRATION AND ENROLLMENT PLAN .................................................................................... 33 
4.1 
Registration Procedure .................................................................................................................................................... 33 
5. 
TREATMENT/INTERVENTION PLAN ................................................................................................................. 33 
5.1 
Screening Assessment ...................................................................................................................................................... 36 
5.2 
Testosterone Lead-in Period ......................................................................................................................................... 38 
5.3 
Testosterone/Nivolumab Combination Period ..................................................................................................... 39 
5.4 
End of Treatment/Treatment Discontinuation Visit .......................................................................................... 40 
5.5 
Follow-up……………………………………………………………………………………………………………………………..40 
5.6 
Correlative/Special Studies ............................................................................................................................................ 41 
6.        STUDY DRUGS……………………………………………………………………………………………………………………................41 
6.1 
Description of Treatments .............................................................................................................................................. 41 
6.2 
Administration, Supply, and Storage ......................................................................................................................... 41 
7. 
DOSE ADJUSTMENT AND DELAY, TREATMENT DISCONTINUATION,  WITHDRAWAL, AND 
TERMINATION CRITERIA ..................................................................................................................................... 42 
7.1 
Dosing and Dose Modifications .................................................................................................................................... 42 
7.2      Dose Delay and Treatment Discontinuation ........................................................................................................... 43 
7.3 
Dose Delay Criteria ............................................................................................................................................................ 43 
7.4  
Criteria to Resume Treatment ...................................................................................................................................... 43 
7.5      Discontinuation Criteria .................................................................................................................................................. 44 
7.6 
Treatment of Nivolumab-Related Infusion Reactions ........................................................................................ 45 
7.7    Treatment Beyond Disease Progression .................................................................................................................. 46 
7.8 
Immunotherapy Adverse Event Management…………………………………………………………………………47 
7.9 
Removal of Subjects from the Study, Therapy Assessment ............................................................................. 47 
7.10    Treatment Compliance..................................................................................................................................................... 48 
7.11    Destruction of Study Drug .............................................................................................................................................. 48 
7.12   Return of Study Drug ........................................................................................................................................................ 48 
8. 
ADVERSE EVENTS ................................................................................................................................................... 49 
8.1 
Definitions .............................................................................................................................................................................. 49 
8.2 
Expectedness ........................................................................................................................................................................ 52 
8.3 
Recording and Grading ..................................................................................................................................................... 52 
8.4 
Reporting Adverse Events .............................................................................................................................................. 53 
9. 
CRITERIA FOR OUTCOME ASSESSMENT/THERAPEUTIC RESPONSE ...................................................... 56 
9.1 
Outcome Assessment ........................................................................................................................................................ 56 
9.2 
Therapeutic Response ...................................................................................................................................................... 57 
9.3 
Response Criteria for Primary and Secondary Endpoints ................................................................................ 59 
9.4 
Criteria for Progressive Disease. .................................................................................................................................. 61 
10. 
DATA REPORTING AND REGULATORY REQUIREMENTS ............................................................................ 61 
10.1  Data Entry .............................................................................................................................................................................. 62 
10.2  Data Management ............................................................................................................................................................... 63 
10.3  Study Monitoring and Quality Assurance ................................................................................................................ 63 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
12 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
10.4  Clinical Trial Agreement .................................................................................................................................................. 64 
11. 
STATISTICAL CONSIDERATIONS ........................................................................................................................ 64 
11.1  Study Endpoints .................................................................................................................................................................. 65 
11.2  Analysis Populations ......................................................................................................................................................... 67 
11.3  Safety Analysis ..................................................................................................................................................................... 68 
12. 
PROTECTION OF HUMAN SUBJECTS ................................................................................................................. 68 
12.1  Ethical Considerations ....................................................................................................................................................... 68 
12.2  Protocol Amendments ........................................................................................................................................................ 68 
12.3  Written Informed Consent ................................................................................................................................................ 68 
12.4  Protection of Privacy .......................................................................................................................................................... 69 
12.5  Terminating or Modifying the Study ............................................................................................................................ 69 
13. 
REFERENCES ............................................................................................................................................................. 71 
 
APPENDIX A: MANAGEMENT ALGORITHM FOR IMMUNO‐ONCOLOGY AGENTS…………………………………...75 
APPENDIX B: PERFORMANCE STATUS CRITERIA……………………………………………………..……………………...….83 
APPENDIX C: LABORATORY MANUAL .......................................................................................................................... 84 
APPENDIX D: GLOSSARY OF ABBREVIATIONS AND ACRONYMS ......................................................................... 87 
APPENDIX E: ACCEPTABLE BIRTH CONTROL METHODS ....................................................................................... 93 
APPENDIX F:  HY’S LAW………………………………………………………………………………………………………………………94 
APPENDIX G:  TUMOR SAMPLE INFORMATION FORM…………………………………………………………………………97 
 
List of Tables: 
 
Table 1         Somatic Gene Analysis of 7 mCRPC Patients Treated with Bipolar Androgen Therapy 
           25 
Table 2         Study Calendar 
   
 
 
 
 
                       
 
           34 
Table 3         Relationship of Adverse Event to Study Drug  
 
 
 
 
           53 
Table 4         RECIST 1.1 Response Criteria for Target Lesions 
 
 
 
                           59 
Table 5          RECIST 1.1 Response Criteria for Nontarget Lesions 
 
 
 
 
           60 
Table 6          Categories for Response to Treatment 
 
 
 
 
 
           67 
 
 
 
List of Figures: 
 
Trial Schema 
 
 
 
 
 
 
 
 
 
 
             7 
Figure 1       Clinical States of Prostate Cancer 
 
 
 
 
 
 
           13 
Figure 2       Androgen Induced Double Strand DNA Breaks in Prostate Cancer Cell Lines Stimulated with  
       High Levels of Androgen. 
 
 
 
 
 
 
                           15 
Figure 3       Castrated NOG Mice Inoculated with LNCaP/A-cells Were Either Exposed to BAT Therapy or  
       Left in a Permanently Castrate State.  
 
 
 
 
 
           16 
Figure 4       Clinical Trial of BAT Plus Etoposide.  
 
 
 
 
 
 
           19 
Figure 5       Results from the Pilot BAT Study in Men with CRPC. 
 
 
 
 
           20 
Figure 6       PSA Values of Extreme Responder Patients Treated with Bipolar Androgen Therapy                      24 
Figure 7       Waterfall Plot of Maximal PSA Change in mCRPC Patients Treated with Combination  
       Checkpoint Inhibitor Therapy  
 
 
 
 
 
           
           26 
Figure 8       CT Imaging of Post BAT mCRPC Patients Before and During Treatment with Checkpoint  
       Inhibition 
 
 
 
 
 
 
 
 
 
           27 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
13 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
1. INTRODUCTION 
 
1.1 
Disease Background 
 
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men, with 
an estimated 180,000 cases annually in the United States (1).  It is the second most common 
cause of cancer mortality in the United States as well, with over 26,000 deaths in 2016 (1).  
The discrepancy between the incidence and mortality numbers demonstrate its potential 
curability if treated while disease is local, as well as the non-lethal nature of some cancers, 
even if not treated definitively.  While many men are cured of their disease, many others 
will unfortunately progress to incurable and lethal metastatic disease. 
 
1.1.1 Clinical States of Prostate Cancer 
 
The course of prostate cancer from diagnosis to death is best categorized as a series of 
clinical states (Fig. 1). These states are defined by the extent of disease and status of 
responsiveness to hormonal therapy. Therapies have been developed for specific states, as 
each state presents unique risks to the patient and different responsiveness of the disease 
to therapy. 
 
 
Figure 1. Clinical states of prostate cancer (2) 
 
1.1.2  Metastatic Castration‐Resistant Disease State 
 
Androgen deprivation therapy (ADT) is the backbone of treatment for metastatic prostate 
 
cancer,  and while ADT is initially highly effective, prostate cancers invariably adapt to a 
 
low-testosterone environment, leading to castration resistance. Studies have demonstrated 
 
that castration-resistant prostate cancer (CRPC) remains dependent on AR signaling. Based 
 
on this understanding, several drugs have been developed and Food and Drug 
 
Administration (FDA)-approved for the treatment of mCRPC, including abiraterone acetate 
 
and enzalutamide. However, we have observed in multiple clinical studies a paradoxical 
 
effect of high dose testosterone resulting in both PSA and radiographic responses in 
 
patients with mCRPC. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
14 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
1.2 
Treatment Background 
1.2.1 
Description and Mechanism of Action 
 
Testosterone cypionate is the oil-soluble form of the androgenic hormone, testosterone. A 
paradoxical inhibition of cell growth has been observed in both androgen-sensitive and 
CRPC cell lines following the addition of high-dose testosterone.(3,4) Several mechanisms 
underlying this paradoxical response to androgens have been identified. First, our group 
and others have showed that AR may be involved in DNA relicensing during cell cycle 
progression.(5-7) Under normal conditions, AR is degraded during the cell cycle. Our group 
found that the AR protein is stabilized in the presence of supraphysiologic levels of 
androgen and remains bound to origins of replication.(5-7) This binding inhibits 
progression through the cell cycle, leading to cell death. Second, androgen-starved prostate 
cancer cells up-regulate both full-length AR and AR splice variants as a survival mechanism. 
The addition of high-dose androgen to the growth media results in the down-regulation of 
these AR splice variants (including AR-V7), potentially re-sensitizing these cells to 
ADT.(8,9) Third, we have shown that following androgen starvation, exposure of CRPC cells 
to high-dose androgen induces double-strand (ds) DNA breaks, resulting in cell growth 
inhibition and decreased clonogenic survival.(10)  Mechanistically, high-dose androgen has 
also been shown to induce structural genomic rearrangements/translocations in CRPC cells, 
including the TMPRSS2-ERG fusion.(11) 
 
 
Nivolumab (also referred to as BMS-936558, MDX1106, or ONO-4538) is a human 
 
monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the 
 
programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane 
 
receptor. PD-1 is a negative regulatory molecule expressed by activated T and B 
 
lymphocytes. Binding of PD-1 to its ligands, programmed death–ligands 1 (PD-L1) and 2 
 
(PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the 
 
interaction between PD-1 and its ligands promotes immune responses and antigen-specific 
 
T-cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in 
 
Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell 
 
cultivation and chromatographic purification technologies. The clinical study product is a 
 
sterile solution for parenteral administration.  
 
 
OPDIVO (nivolumab) is approved for the treatment of several types of cancer in multiple 
 
regions including the United States (US, Dec-2014), the European Union (EU, Jun-2015), and 
 
Japan (Jul-2014). Nivolumab is also being investigated in various other types of cancer as 
 
monotherapy or in combination with other therapies, and as single-dose monotherapy for 
 
the treatment of sepsis.  
 
1.2.3     Preclinical Studies  
 
High-dose testosterone, also referred to as Bipolar Androgen Therapy (BAT): 
The mechanisms underlying the growth-suppressive effects of high levels of androgens in 
prostate cancer cells in vitro and in vivo is likely highly complex. Recent evidence from our 
group suggests that one mechanism may involve the formation of androgen-induced 
Topoisomerase II beta (TOP2B)-mediated double strand breaks at AR target genes (Figure 
2).(10) Studies have shown that estrogen signaling in breast cancer cells involves the co-
recruitment of Estrogen receptor and TOP2B to estrogen receptor target sites, where 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
15 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
TOP2B introduces transient double strand breaks. We hypothesized that such a mechanism 
may be involved in androgen signaling in prostate cancer cells and that at high doses of 
androgens, such breaks may persist and ultimately lead to growth suppression. In support 
of this, we observed that stimulation of androgen-deprived LNCaP cells with 
dihydrotestosterone (DHT) led to recruitment and catalytic activity of TOP2B at AR target 
sites in the TMPRSS2 enhancer as well as at other known AR target sites. At high doses of 
DHT, this TOP2B recruitment and catalytic activity was associated with significant 
formation of AR and TOP2-dependent persistent double strand breaks at the TMPRSS2 
gene, as observed by fluorescence in situ hybridization (FISH) assay which is capable of 
detecting genomic breaks on an individual cell basis.(10) Such breaks likely occurred 
throughout the genome at AR target sites since we observed numerous γH2A.x foci, a 
marker for double strand break formation, throughout the nucleus in response to 
stimulation of LNCaP cells with high-dose DHT (Figure 2). In further confirmation of this, 
we also observed recruitment of ATM, a double strand break repair signaling protein, to AR 
target sites in PSA and TMPRSS2, genes present on different chromosomes in the cell. These 
findings suggest that exposure of prostate cancer cells from patients with CRPC to high 
doses of testosterone may induce growth suppression due to the accumulation of androgen- 
mediated, TOP2-induced double strand DNA breaks.(10) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Androgen-induced double strand DNA breaks in prostate cancer cell lines 
stimulated with high levels of androgen. Stimulation of androgen-deprived LAPC4 cells 
(control) to high levels of DHT (DHT) leads to numerous double strand breaks throughout 
the nucleus as evidenced by the accumulation of numerous γH2A.x foci, a marker for 
formation of double strand breaks.  
 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
16 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Recently, the Denmeade laboratory has explored a mechanism for growth inhibition by 
testosterone (T) in CRPC cells. These studies document that the increase in AR expression 
observed in these cells in the low T environment creates a unique therapeutic vulnerability 
to selectively kill CRPC cells. This is based upon the fact that AR is involved in DNA 
relicensing and DNA replication and AR must be degraded in each cell cycle for proper 
relicensing to occur. Overstabilization of the increased levels of AR observed in CRPC with 
supraphysiologic testosterone prevents complete degradation of AR via the proteasome 
during mitosis. This was demonstrated by in vivo treatment of resistant human LNCaP 
prostate cancer xenografts with T implants to achieve supraphysiologic serum T- levels.(5) 
This treatment resulted in significant growth inhibition (Figure 3a). These growth-inhibited 
cells had similar amount of cells with nuclear AR in the nucleus and Ki-67 positivity (Figure 
3a). However, in xenografts treated with supraphysiologic T, the Cell Death Index was ~ 3- 
fold higher.(5) More strikingly, the percent of cells staining positive for AR in mitosis was 
approximately 10-fold higher in cells exposed to supraphysiologic T versus castrate-only 
animals (Figure 3b). This data suggests that CRPC cells that have not properly relicensed 
DNA, can die when they attempt to proceed through a subsequent cell cycle. Thus, based on 
this proposed mechanism, prostate cancer cells that maintain high AR levels will be 
vulnerable to cell death when exposed to supraphysiologic T conditions due to their 
inability to rapidly auto-regulate AR to lower levels. Due to the bipolar cycling between high 
and low serum T achieved with BAT, those cells that do manage to survive the high T 
environment through adaptive down-regulation of AR will become vulnerable to cell death 
when suddenly exposed to low T conditions that occur over the cycle of BAT.  
 
  
 
Figure 3. Castrated NOG mice inoculated with LNCaP/A-cells were either exposed to BAT 
therapy (via an implanted testosterone filled capsule that was placed and removed at two 
week intervals) or left in a permanently castrate state (diamond versus box). (A) Evaluation 
of indicated parameters in LNCaP/A- cells growing in castrate mice vs. castrate mice 
supplemented with subcutaneous testosterone-filled silastic implants. (B) 
Immunohistochemical staining for AR in harvested LNCaP/A- xenografts growing in 
castrate vs. castrate + T-pelleted mice. Blue arrows indicate mitotic figures. 
 
Nivolumab: 
Tumors can express tumor-specific antigens as a result of mutational burden, and ongoing 
immune surveillance is believed to control the development of many tumors. Tumor 
progression may depend on the acquisition of mechanisms that permit them to evade an 
effective immune response. One such mechanism of evasion may be the expression of 
ligands, which engage inhibitory receptor(s) on anti-tumor T cells of many tumors. PD-L1 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
17 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
expression has been found on a number of tumors and may be a mechanism by which 
tumors can directly engage PD-1 to evade an effective anti-tumor immune response.(12-14) 
Expression of IFN-γ by activated T cells is known to induce PD-L1 expression in tumors.(15) 
PD-L1 expression has been associated with poor prognoses in renal,(16-18) 
esophageal,(19) gastric,(20) ovarian,(14) pancreatic,(21) and lung cancers.(22)  PD-1 
engagement on T cells by PD-L1-positive APC or PD-L1-positive tumor cells in the tumor 
microenvironment may limit effective immune responses. Conversely, PD-L1 expression 
may be a positive prognostic factor as it may indicate infiltration of tumor-specific T cells 
that secrete IFN-γ, which up-regulates PD-L1 expression. Consistent with this hypothesis is 
the co-localization of lymphoid cell infiltrates and PD-L1 staining observed in human 
melanoma lesions.(23) 
 
Studies in multiple tumor models using a chimeric murine anti-mouse PD-1 antibody 
showed that PD-1 blockade has anti-tumor activity.(24) Blocking PD-1 in PD-L1-positive 
tumors may reverse the inactivation of tumor-specific effector T cells at the tumor site, as 
well as activate anti-tumor responses that are limited by PD-L1 expression on “host” DC or 
APC. The anti-tumor effects of anti-PD-1 observed in several murine models suggest that 
both PD-L1-positive and PD- L1-negative tumors may be targeted using this approach. In 
addition, in several tumor models in which anti-PD-1 has proved ineffective, PD-1 blockade 
can be combined with vaccines or other immunomodulatory antibodies for improved 
therapeutic efficacy.(25-27) PD-1 blockade by Nivolumab is a promising avenue to pursue 
as an anti-tumor therapy for recurrent or treatment-refractory malignancies.  
 
1.2.4    Clinical Studies 
BAT: 
Up until recently, there had been very limited clinical experience in the PSA-era treating 
CRPC patients with testosterone. Brendler et al. (1949) at the Brady Urological Institute 
reported in the Archives of Surgery on the use of parenteral testosterone in several men 
with advanced CRPC.(28) They observed considerable improvement in several men that 
included decreased pain, decreased prostate size, and decreases in acid and alkaline 
phosphatase. In a second study, Prout and Brewer (1967) reported in Cancer on the 
treatment of men who had been either untreated or recently castrated or long term 
castrates with parenteral testosterone.(29) Five relapsed patients in the long term castrate 
group received testosterone for at least one month and 4 of 5 had subjective improvement. 
Five remaining patients in the long term castrate group received testosterone for 1-19 days, 
with each progressing and subsequently coming off therapy. Acid phosphatase declined in 
2/5 men receiving a longer course of testosterone. Remarkably, one man in this group 
admitted to hospital with severe back pain, weakness, and anorexia had a 10 month 
response with complete cessation of pain, excellent appetite, and weight gain with a 
decrease in acid phosphatase from 50 to 5 units.  
In contrast, a number of studies during the 1960-70s evaluated the use of T-priming in 
combination with 32P-sodium phosphate to treat men with CRPC and severe pain due to 
widespread bony metastases.(30,31) In these studies, initial T-priming using a variety of 
parenteral dosing regimens was associated with transient increase in bone pain during the 
first week followed by excellent pain palliation following administration of 32P. Similar 
results were observed in studies led by Manni who evaluated T- priming with 
chemotherapy in the 1980’s.(32) These studies were also conducted in men with CRPC and 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
18 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
pain due to widely metastatic disease. In these studies, increased bone pain was also 
observed in men upon initial treatment with oral androgens. The increased pain in these 
studies typically occurred within days of T administration. Thus, given this time frame, it is 
likely the increased pain was due to T-stimulation of inflammation/cytokine release within 
sites of bone metastases rather than a direct effect on tumor growth. Such rapid change is 
also seen in men with bone pain upon initially starting ADT. Marked improvement in pain 
after ADT often occurs within hours of treatment, an effect not due to tumor death but 
rather a rapid change in expression of pain-promoting gene products.  
Two contemporary Phase I studies were reported describing the results of the use of 
transdermal T as therapy for men with CRPC who had minimal to moderate disease burden 
and no pain due to prostate cancer. In the first study, Szmulewitz et al. (2009) evaluated the 
effect of increasing doses of transdermal T in 15 men with early CRPC (rising PSA and 
minimal bone disease).(33) Five men each were treated with 2.5, 5.0 or 7.5 mg/day of 
transdermal T which brought the median concentration of T from castrate to 305, 308, and 
297 ng/dL respectively. In this study, no grade 3 or 4 toxicities were observed with the 
exception of one man who was taken off study at week 53 for grade 4 cardiac toxicity. Only 
one patient had symptomatic progression and three patients (20%) had a decrease in PSA 
(largest was 43%). Patients treated at the highest T dose had a prolonged time to 
progression that did not reach statistical significance, most likely due to the small cohort 
size. In the second study, Morris et al. (2016) evaluated the effect of transdermal T at a dose 
of 7.5 mg/day administered for 1 week (n=3), 1 month (n=3) or until disease progression 
(n=6) in 12 patients with CRPC.(34) They observed no grade 3 or 4 toxicities and no pain 
flares. Eugonadal serum T levels were reported for this study. No objective responses were 
observed. Four patients had at least 20% declines and one achieved a > 50% PSA decline.  
Neither of these Phase I studies achieved the supraphysiologic levels of serum T that can be 
reached with FDA-approved doses of T administered as an intramuscular depot.(35) 
However, the levels of serum T achieved were in the high-end of the eugonadal range. 
Remarkably, although the studies were considered “negative” from the standpoint of 
disease response, in both studies the administration of parenteral T to men with CRPC was 
very well-tolerated and did not result in significant worsening of disease or symptoms, 
including pain flares. While only one patient out of 27 from the combined studies had a 
reported > 50% decline in PSA, smaller PSA declines were observed in a few of the patients 
on these two studies with a trend toward a dose-responsive effect, suggesting a potential for 
therapeutic benefit in some patients.(33,34)  
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
19 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
  
 
Figure 4. Clinical trial of BAT plus etoposide. (A) Schematic of study design. (B) Baseline 
characteristics of patients on study. (C) Mean serum testosterone levels at indicated time 
points for patients on study.  
 
Based on the preclinical results and potential mechanisms for growth inhibition that include 
androgen-induced double strand breaks and the stabilization of AR preventing relicensing, 
we have conducted a pilot study evaluating the efficacy and safety of pharmacologic doses 
of testosterone to produce supraphysiologic T levels in conjunction with oral etoposide (E) 
in chronically castrated men with rising PSA and CRPC (Figure 4a).(36) Patients who had 
been continuously castrate for more than one year with minimal metastatic disease burden 
(≤ 5 total bone metastases and ≤ 10 total sites of metastases), and/or rising PSA were 
eligible (Figure 4b). To achieve rapid cycling between supraphysiologic and near-castrate 
serum T, patients received an intramuscular injection of 400 mg testosterone cypionate (i.e. 
BAT) every 28 days. For the first 3 cycles of therapy, patients received BAT plus oral 
etoposide 100 mg PO/day, days 1-14 of a 28 day cycle. After 3 cycles, PSA and objective 
responses were assessed. Those patients with a PSA that was declining from peak levels and 
no objective evidence of disease progression or worsening pain were continued on therapy. 
Given the toxicity associated with etoposide and the lack of clinical response in an earlier 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
20 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
trial,(37) patients who were responding after 3 cycles of testosterone plus etoposide were 
continued on testosterone alone based on protocol amendment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Results from the pilot BAT study in men with CRPC. (A) Waterfall plot of best PSA 
response with 7/14 men and 4/14 men achieving PSA declines > 30% and > 50%, 
respectively; (B) Representative patterns of PSA response in pilot study; PSA and serum T 
level in non-responder; (C) PSA response in patient receiving 3 cycles of T + E and then 13 
additional cycles of T alone. Patient demonstrated renewed sensitivity to ADT after 
progressing on BAT; (D) Objective lymph node complete and partial response after 3 cycles 
of BAT + E.  
 
Seven of fourteen patients had a decline in PSA from baseline value (Figure 5a). An eighth 
patient progressing after testosterone treatment for 6 months, had a decline in PSA upon 
reaching castrate-level testosterone. Non-responders came off trial after 3 cycles due to PSA 
progression. Overall, three patterns of PSA response were observed (Figure 5b). For the 
seven patients that had a PSA decline, the median time to PSA progression was 221 days 
(range, 95 to 454 days).  
  
The dose of 400 mg testosterone cypionate produces supraphysiologic levels > 1500 ng/dL 
within 2 days post injection (Figure 4c). At baseline, ten subjects had RECIST-evaluable soft 
tissue metastases (Figure 4b). Of these patients, two (20%) had progressive disease (PD), 
three (30%) had stable disease (SD) after a median follow-up of 91 days (range, 87 to 92 
days), four (40%) had partial responses (PRs), and one (10%) had a complete response 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
21 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
(CR) (Figure 5d). None of the 14 patients completing 3 months of therapy developed new 
bone metastases. One patient with > 50% decrease in PSA had intensification of an isolated 
tibial metastases on bone scan and was removed from study despite decline in PSA levels. 
No other patient developed worsening pain on study.  
 
Two clinical trials involving high-dose T are ongoing at Johns Hopkins: 1. RESTORE Trial 
(J1416) - A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy 
(BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer 
Progressing on Combined Androgen Ablative Therapies; 2. TRANSFORMER trial (J14146) - 
A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in 
Asymptomatic Men with Castration-Resistant Metastatic Prostate Cancer.   
Nivolumab 
This updated Investigators Brochure (IB) references the most recent USPI and EU SmPC as 
the basis for the current state of knowledge on Nivolumab for use in humans with cancer. 
The approved USPI and SmPC are provided in Appendix 1 and Appendix 2 of the IB, 
respectively. The USPI and SmPC summarize Nivolumab monotherapy clinical data for 
melanoma (based on CA209037 and CA209066), SQ NSCLC (based on CA209063 and 
CA209017), NSQ NSCLC (based on CA209057), RCC (based on CA209025), Classical 
Hodgkin Lymphoma (cHL; based on CA209205 and CA209039), and urothelial carcinoma 
(UC; based on CA209275 and CA209032), as well as clinical data for Nivolumab in 
combination with Ipilimumab for melanoma (based on CA209004, CA209069, and 
CA209067). In addition, the USPI describes Nivolumab monotherapy clinical data for 
SCCHN (based on CA209141). Data from clinical studies that are relevant to ongoing clinical 
investigations in oncology that are not in the approved USPI and SmPC or to subjects with 
sepsis are included in this updated IB.  
The PK, clinical activity, and safety of Nivolumab have been assessed in approximately 75 
clinical studies sponsored by BMS or ONO. The description and status of studies with 
reference safety information are provided in Appendix 4 of the IB. Across those studies, 
approximately 16,900 subjects have received Nivolumab monotherapy in single- or 
multiple-dose Phase 1/2/3 studies or studies with Nivolumab in combination with other 
therapeutics (Ipilimumab, cytotoxic chemotherapy, anti-angiogenics, and targeted 
therapies). Results from the ongoing studies are preliminary and are subject to change.  
Nivolumab has demonstrated clinical activity in NSCLC, melanoma, RCC, cHL, SCCHN, UC 
(approved indications) and other tumor types (Section 5.4 of the IB) as monotherapy or in 
combination with Ipilimumab or other therapeutics. The majority of responses were 
durable and exceeded 6 months. In randomized-controlled studies, Nivolumab 
monotherapy demonstrated statistically significant improvement in OS over standard-of-
care in subjects with advanced or metastatic melanoma, subjects with advanced or 
metastatic NSCLC, subjects with advanced RCC, and subjects with recurrent or metastatic 
SCCHN.  In randomized-controlled studies, Nivolumab in combination with Ipilimumab 
demonstrated statistically significant improvement in PFS and ORR over Ipilimumab 
monotherapy in subjects with advanced or metastatic melanoma.  
All available data suggest that Nivolumab monotherapy has a consistent AE profile across 
tumor types. The safety profile is generally consistent across completed and ongoing clinical 
trials, with no maximum tolerated dose (MTD) reached at any monotherapy dose tested up 
to 10 mg/kg. There was no pattern in the incidence, severity, or causality of AEs to 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
22 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Nivolumab dose level. The safety profile of Nivolumab in combination with Ipilimumab was 
consistent with the mechanisms of action of Nivolumab and Ipilimumab. The nature of the 
AEs was similar to that observed with either agent used as monotherapy; however, both 
frequency and severity of most AEs were increased with the combination. A dose of 3 
mg/kg Nivolumab/3 mg/kg Ipilimumab exceeded the MTD, and both 1 mg/kg 
Nivolumab/3-mg/kg Ipilimumab and 3 mg/kg Nivolumab/1 mg/kg Ipilimumab were 
identified as the MTD. Across all studies conducted to date, drug-related AEs have included 
pulmonary toxicity, renal toxicity (including acute renal failure), endocrine abnormalities, 
GI toxicity, dermatologic toxicity (including rash), and hepatotoxicity. For Nivolumab 
monotherapy and combination therapy, the majority of these AEs have been managed 
successfully with supportive care and, in more severe cases, a combination of dose delay, 
permanent discontinuation, and/or use of corticosteroids or hormone replacement therapy 
(endocrinopathies) as instructed in the management guidelines provided in Appendix 3 of 
the IB.  
In addition to BMS-sponsored ongoing studies, 22 studies sponsored by ONO 
Pharmaceuticals, Ltd. and conducted in Japan, Korea, and/or Taiwan are included in the 
reference safety information in Section 5.6 of the IB. Brief descriptions of these studies are 
provided in Appendix 4 of the IB. The studies are not under any US investigational new drug 
application (IND). Efficacy and safety information from ONO studies (ONO-4538-01, ONO-
4538-04, ONO-4538-07, ONO-4538-12, ONO-4538-13, and ONO-4538-14) are provided in 
Section 5.4 and Section 5.5 of the IB.  
All studies were conducted in accordance with Good Clinical Practice, as defined by the 
International Conference on Harmonisation and in accordance with the ethical principles 
underlying European Union Directive 2001/20/EC and the US Food and Drug 
Administration Code of Federal Regulations (CFR), Title 21, Part 50 (21CFR50).  
 
1.2.5     Clinical Safety Summary 
 
 
BAT: 
The majority of adverse events (AEs) occurred during the initial phase of treatment and 
were largely consistent with known side effects of etoposide. Initial-phase side effects were 
mostly low grade (i.e. ≤ Grade 2) and included: nausea (N=10), fatigue (N=9), alopecia 
(N=9), edema (N=8), and neutropenia (N=3), as listed in the table below. Two patients had a 
grade 3 asymptomatic, subsegmental pulmonary embolism. Two subjects did not complete 
the initial treatment phase, one individual was taken off study after developing grade 2 
priapism, and a second individual expired due to pneumonia/neutropenic sepsis. AEs 
occurring during the BAT monotherapy phase of the trial were rare and low grade. Only 
four subjects experienced an AE during this phase, and all but three AEs were grade 1. 
Grade 2 events included alopecia and an elevated creatinine in one subject and grade 2 
nausea in a separate subject.  
 
None of the 14 patients developed new pain, skeletal events or urinary obstruction due to 
prostate cancer. Although quality of life was not formally evaluated in the study, most 
subjects reported enhanced well-being and increased functional activity. Patients with 
intact sexual function prior to ADT had return of sexual function and libido on BAT.  
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
23 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nivolumab: 
 
The overall safety experience with Nivolumab as a monotherapy, is based on experience in 
 
approximately 11,000 subjects treated to date.  For monotherapy, the safety profile is 
 
similar across tumor types. The only exception is pulmonary inflammation adverse events 
 
(AEs), which may be numerically greater in subjects with NSCLC, because in some cases, 
 
it can be difficult to distinguish between Nivolumab-related and unrelated causes of 
 
pulmonary symptoms and radiographic changes. There is no pattern in the incidence, 
 
severity, or causality of AEs to Nivolumab dose level.  A detailed list of AEs for patients 
 
treated with Nivolumab as monotherapy on clinical trials can be found in Table 5.6.1-1 in 
 
the IB. 
 
 
In several ongoing clinical trials, the safety of Nivolumab in combination with other 
 
therapeutics such as Ipilimumab, cytotoxic chemotherapy, anti-angiogenics, and targeted 
 
therapies is being explored. Most studies are ongoing and, as such, the safety profile of 
 
Nivolumab combinations continues to evolve.    
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
24 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
1.3 
Rationale 
 
1.3.1 
Rationale for Conducting the Study 
 
BAT and DNA Repair:  
We have discovered a provocative association between germline and/or somatic DNA-
repair mutations and response to BAT. Based on prior studies, the incidence of germline 
mutations in DNA-repair genes in mCRPC patients is 8-12%, with somatic DNA-repair 
mutations approaching 20-25%. As mentioned, we have recently identified a correlation 
between long term (“exceptional”) responders to BAT and the presence of mutations in 
homologous recombination DNA repair genes. Our index case was an enzalutamide-
pretreated patient with mCRPC who achieved a durable (> 24 mo) complete radiographic 
and serologic response following treatment with BAT (Figure 6).(38) Tumor DNA 
 
sequencing found inactivating mutations in both BRCA2 (with LOH) and ATM (mono-
 
allelic), which were then confirmed on germline DNA testing (i.e. these were both inherited
 
mutations). We have since systematically sequenced tumor/germline DNA from patients 
 
receiving BAT and, remarkably, have detected DNA repair mutations in the majority of 
 
responders (Table 1). Overall, our preliminary unpublished findings suggest an 80% 
 
response rate to BAT (4/5) in men with DNA repair mutations, implying a provocative 
 
association between DNA repair-deficient prostate cancer and BAT responsiveness. This is a 
 
rational inference based on the fact that BAT may induce dsDNA breaks that may go 
 
unrepaired in the setting of homologous recombination defects. 
 
 
Nilutamide 
150 mg qd 
Ketoconazole 
200 mg d 
Ketoconazole 
400 mg d 
Enzalutamide 
160 mg qod 
Testosterone Cypionate  
400 mg IM q 28 days 
PSA Level (ng/ml) 
Months 
Figure 6. PSA values of Extreme Responder Pa ent to Bipolar Androgen Therapy 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
25 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
 
 
Immune Checkpoint Blockade and DNA Repair:  
Two randomized phase III trials involving single-agent checkpoint (CTLA-4) inhibitors in 
mCRPC patients did not meet their primary endpoints.(39,40) However, a small subset 
(~20%) of mCRPC patients did derive clinical benefit, although the molecular 
characteristics of these patients are unknown. In pilot studies conducted at Johns Hopkins, 
we have observed significant responses to checkpoint inhibition in several heavily 
pretreated mCRPC patients with DNA repair defects (Figure 7). For instance, two patients 
(#1: MSH6-mutated; #2: BRCA2-mutated) achieved a PSA50 response following combined 
PD-1/CTLA-4 checkpoint inhibition using Ipilimumab plus Nivolumab. Patient #1 also had a 
partial radiographic RECIST response and remains progression-free for > 6 months.  Patient 
#2 had over 20 sites of symptomatic bone metastases at that start of therapy. Following 
combination checkpoint inhibition, his pain disappeared (pain score: 6/10  0/10) and his 
clinical response is ongoing after 9 months. A third mCRPC patient (#3: ATM-mutated) 
achieved a partial radiographic RECIST response without a PSA response. A fourth patient 
(#4: POLH-mutated) also had a RECIST response without a PSA response. Moreover, those 
patients with a DNA repair mutation had significantly improved radiographic-PFS (HR 0.28, 
p=0.027) and PSA-PFS (HR 0.14,P=0.001) compared to DNA repair-proficient patients. 
Similar to the efficacy of checkpoint inhibitors in patients with MSI-High (mismatch repair-
deficient) colon cancer, we speculate that a benefit of immunotherapy may be observed in 
mCRPC patients with germline and/or somatic mutations in DNA repair genes, including 
homologous recombination genes (i.e. not just MMR genes), thus potentially expanding the 
pool of mCRPC patients that may be susceptible to immune checkpoint blockade. 
 
Pa ent 
Max PSA Change (%) 
DDR Muta ons 
Sequencing results 
1 
100 
None 
Not done 
2 
37 
None 
POSITIVE for TMPRSS2‐ERG Fusion, TP53 muta on and 
addi onal altera ons.   
3 
-11
 1 copy loss of BRCA2 
PTEN homozygous dele on, TP53 p.R175H point 
muta on and copy neutral LOH, TMPRSS2‐ERG 
fusion, 1 copy loss of RB1, 1 copy loss of BRCA2 
4 
-55
CDK12 p.G923V  muta on and 
copy neutral LOH, BRCA2 
p.Y1762* muta on and 1 copy 
loss 
FOXA1 p.H247Q muta on, TP53 p.Y163C  muta on 
and copy neutral LOH, CDK12 p.G923V  muta on 
and copy neutral LOH, BRCA2 p.Y1762* muta on 
and 1 copy loss, RB1 Dele on exon 4 and 1 copy 
loss, HOXB13 p.G84E germline variant and LOH 
5 
-74
CHD1 copy loss, chr13 copy 
loss (BRCA2 region) 
AR amplifica on, TP53 muta on, ERBB4 muta on, FOXA1
muta on, CHD1 copy loss, and chr13 copy loss in the 
region of BRCA2 and RB1 
6 
-85
ATRX‐ATAD2B gene fusion 
(loss of ATRX func on) 
PTEN homozygous dele on, TP53 p.R175H point 
muta on (hot spot), AR p.W742C (bicalutamide 
resistance), TMPRSS2‐ERG, ATRX‐ATAD2B gene 
fusion (out‐of‐frame, loss of ATRX func on) 
7 
-94
None 
PTEN copy loss, TP53 muta on 
Table 1. Soma c Gene Analysis of 7 mCRPC pa ents treated with Bipolar Androgen Therapy 
DDR = DNA Damage Response Genes 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
26 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
 
 
BAT/Immunotherapy Combination:  
Even more notably, we have observed intriguing tumor responses in two mCRPC 
patients with intact DNA repair processes (i.e. no repair gene mutations) that were treated 
sequentially (on two different trials) with BAT followed by PD-1 inhibition, who achieved 
dramatic PSA/RECIST responses to PD-1 blockade (Figure 8). Patient #1 initially achieved a 
PSA50 response to BAT, which lasted 11 months, before developing subsequent progression. 
Upon starting checkpoint inhibition following BAT, his PSA level dropped from 56 ng/mL to 
4 ng/mL in the first 12 weeks, accompanied by a dramatic soft tissue response (Figure 8A). 
Patient #2 also initially achieved a PSA50 response to BAT lasting 6 months, but eventually 
progressed. Following subsequent treatment with Pembrolizumab, his PSA dropped from 
692 ng/mL to 3 ng/mL, with a partial radiographic response after only 3 months of anti-PD-
1 therapy (Figure 8B). Importantly, neither patient had a DNA repair mutation although 
both benefited dramatically from PD-1 inhibition following BAT. Based on these 
preliminary data, we believe that further study of BAT with a checkpoint inhibitor is 
warranted. 
 
 
 
‐100.00% 
‐75.00% 
‐50.00% 
‐25.00% 
0.00% 
25.00% 
50.00% 
75.00% 
100.00% 
Percent Change 
PSA responses 
DRD ‐ 
DRD + 
Figure 7. Waterfall Plot of Maximum PSA Change (%) in mCRPC Pa ents Following Treatment  
       With Combina on Checkpoint Inhibitor Therapy   
 
    Red Bars– DNA Repair Deficient; Blue Bars – Intact DNA Repair  
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
27 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
 
In this trial, we will adopt a timed-sequential approach, whereby patients will first receive 
BAT and followed 12 weeks later by the addition of Nivolumab. We hypothesize that (1) 
BAT-induced dsDNA breaks/rearrangements will result in neoantigen formation and 
increased sensitivity to Nivolumab (primary hypothesis); that (2) mCRPC patients with 
germline/somatic mutations in DNA repair genes will derive the greatest clinical benefit 
from both BAT and Nivolumab; and (3) that the combination of BAT with Nivolumab will be 
safe and well-tolerated in mCRPC patients resulting in minimal grade 3/4 toxicities. 
 
1.3.2 
Rationale for Dosage Selection 
Nivolumab will be administered at a flat dose of 480mg IV given every 4 weeks until 
progression. Nivolumab has been extensively studied in humans at doses ranging from 1-
10mg/kg every 2 weeks to 0.3-10mg/kg every 3 weeks.  Using these doses, the clinical 
pharmacology of Nivolumab is well-established.  Based on the exposure-response 
relationships for efficacy and safety, the benefit-risk profile of Nivolumab 480mg given 
every 4 weeks is predicted to be similar to the 3mg/kg dosing across multiple tumor types 
(Zhao X et al. A Model‐Based Exposure–Response (E–R) Assessment of a Nivolumab (NIVO)  4‐
Weekly (Q4W) Dosing Schedule Across Multiple Tumor Types. AACR 2017: CT101.)  
Testosterone cypionate will by administered at a dose of 400mg IM every 28 days (4 
weeks). This dose of testosterone has been shown to be both safe and efficacious in mCRPC 
patients. 
 
 
Pa ent #1 
PSA Decline: 92% 
Pre‐Treatment 
On‐Treatment 
Pa ent #2 
PSA Decline: 99.6% 
Figure 8. CT Imaging of Post‐BAT mCRPC Pa ents Before and During Treatment  
       With Checkpoint Inhibi on.  Red arrows indicate target lesion.  
A. 
B. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
28 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
2.  
OBJECTIVES 
2.1 
Primary Objective 
The primary objective is to estimate the PSA response rate (PSA50) in patients with 
metastatic castration-resistant prostate cancer (mCRPC). This will serve as an initial 
exploration of this drug-drug combination’s activity in this disease state. 
2.2 
Secondary Objectives 
 
Safety/Tolerability, defined as incidence of CTCAE grade ≥ 3 toxicities experienced by 
patients on the trial. 
 
PSA progression-free survival, defined as the time from initiation on BAT until PSA increase 
of 25%, confirmed with another measurement at least 4 weeks later (PCWG3). 
 
Progression-free survival, defined as the time to radiographic or clinical progression or 
death, whichever comes first.  Based on RECIST version 1.1 and PCWG3 definitions 
including: 1. Progression of soft tissue lesions according to RECIST 1.1; 2. Progression of 
bony lesions detected by bone scan according to PCWG3 criteria; 3. Radiographically-
confirmed spinal cord compression or pathological fracture due to malignant progression, 
or other clinical event deemed to be cancer-related. 
 
Objective response rate, defined as the proportion of patients achieving a complete/partial 
response in target lesions (RECIST 1.1). 
 
Durable progression-free survival (Durable-PFS), defined as the proportion of patients 
without clinical or radiographic progression (as defined by PCWG3) or death at 24 weeks 
from the start of treatment. 
 
Overall survival will be defined as the time from study enrollment to death or up to 2 years 
after the last dose of study treatment.   
2.3 
Correlative/Exploratory/Tertiary Objectives 
 
To estimate the percentage of patients with somatic (tumor) or germline mutations in 
homologous repair (HR) and mismatch DNA repair mutations. 
 
To measure changes in gamma-H2AX, RAD51, 53BP1 (DNA damage markers) following 
treatment with BAT and at progression on BAT/Nivolumab. 
 
To measure changes in CD4, CD8, FOXA3, Ki-67, PD-1, PD-L1 tumor levels with BAT alone 
and at progression following BAT/Nivolumab. 
 
To investigate any association between PD-1 and PD-L1 expression in tumor specimens and 
PSA50 response rates. 
 
To explore the relationship between mutation-associated neoantigens (MANAs) and tumor-
associated neoantigens (TAAs) and clinical outcomes. 
 
To characterize the effect of BAT on production of inflammatory chemokines and cytokines. 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
29 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
3. 
PATIENT SELECTION 
3.1 
Target Population 
The target population is men with metastatic castration-resistant prostate cancer with prior 
treatment of at least ONE novel AR-targeted therapy such as abiraterone acetate or 
enzalutamide. One prior chemotherapy agent for mCRPC will be allowed but is not required. 
3.2 
Expected Enrollment 
A total of 44 patients will be included in this study. The first patients are expected to be 
enrolled in Q3/Q4 2018. Accrual is expected to be completed in 18 months once the 
protocol has been approved by the IRB at each participating institution. 
3.3 
Inclusion Criteria 
To be included in this study, patients should meet all of the following criteria: 
 
Willing and able to provide signed informed consent. 
 
Males aged 18 years of age and above. 
 
Histological or cytologic proof of adenocarcinoma of the prostate. 
 
Known castration-resistant disease, defined according to PCWG3 criteria as: 
 
Castrate serum testosterone level ≤ 50 ng/dL (≤ 1.7 nmol/L). 
 
Subjects who have failed initial hormonal therapy, either by orchiectomy or 
by using a GnRH agonist in combination with an anti-androgen, must first 
progress through anti-androgen withdrawal prior to being eligible. The 
minimum timeframe to document failure of anti-androgen withdrawal will 
be 4 weeks. 
 
Serum PSA progression defined as 2 consecutive increases in PSA over a 
previous reference value within 6 months of the first study treatment, each 
measurement at least 1 week apart. 
 
Or 
 
Documented bone lesions by the appearance of ≥ 2 new lesions by bone 
scintigraphy or dimensionally-measureable soft tissue metastatic lesion 
assessed by CT or MRI. 
 
Absolute PSA ≥ 2.0 ng/mL at screening.   
 
Must have PSA and/or radiographic progression on AT LEAST ONE novel AR-
targeted therapy (abiraterone acetate, enzalutamide). One prior chemotherapy 
agent for mCRPC will be allowed. 
 
Prior treatment with abiraterone, enzalutamide, bicalutamide, and/or ketoconazole 
is allowed. There is no limit on the maximum number or types of prior hormonal 
therapies received. 
 
Must be maintained on a GnRH analogue or have undergone orchiectomy. 
 
Radiographic evidence of metastatic disease by CT scan and/or bone scan, 
performed within the prior 4 weeks of the screening visit. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
30 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
Must have a soft tissue lesion available for biopsy collection to perform tumor tissue 
analysis. 
 
Karnofsky Performance Status (KPS): ≥ 70% within 28 days before start of study 
treatment (ECOG ≤ 2) (See Appendix B). 
 
Participants must have normal organ and bone marrow function measured within 
28 days prior to administration of study treatment as defined below: 
 
Hemoglobin ≥ 9.0 g/dL with no blood transfusion in the past 28 days   
 
Absolute neutrophil count (ANC) ≥ 1.0 x 109/L 
 
Platelet count ≥ 100 x 109/L 
 
Total bilirubin within institutional upper limit of normal (ULN) (In patients 
with Gilbert’s syndrome, total bilirubin < 1.5x institutional ULN will be 
acceptable) 
 
Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic 
Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic 
Pyruvate Transaminase (SGPT)) within institutional upper limit of normal  
 
Participants must have Creatinine Clearance estimated using the Modified 
Cockcroft-Gault equation of ≥ 40 mL/min: 
Estimated Creatinine Clearance    = 
(140-age [years]) x weight (kg) 
 
 
 
 
 
 
 serum creatinine (mg/dL) x 72 
 
Participants must have a life expectancy ≥ 6 months. 
 
Male participants and their partners, who are sexually active and of childbearing 
potential, must agree to the use of two highly effective forms of contraception in 
combination [see appendix E for acceptable methods], throughout the period of 
taking study treatment and for 7 months after the last dose of Nivolumab to prevent 
pregnancy in a partner. 
 
No evidence (within 5 years) of prior malignancies (except successfully treated 
basal cell or squamous cell carcinoma of the skin). 
3.4 
Exclusion Criteria 
Patients that meet any of the criteria listed below will not be eligible for study entry: 
 
Has received external-beam radiotherapy within the last 2 weeks prior to start of 
study treatment. 
 
Prior oral anti-androgen (e.g. bicalutamide, nilutamide, enzalutamide, apalutamide), 
or androgen synthesis inhibitor (e.g. abiraterone, orteronel) within the past 2 weeks 
is not permitted. 5-alpha reductase inhibitor therapy (e.g. finasteride, dutasteride) is 
allowed, as long as subject has been stable on medication for past 6 months. 
 
Prior treatment with chemotherapy for the treatment of metastatic hormone-
sensitive prostate cancer is allowed if the last dose of chemotherapy was ≥ 6 months 
prior to enrollment.  In addition, one prior chemotherapy agent for mCRPC will be 
allowed after a minimum wash-out period of 4 weeks prior to enrollment. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
31 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
Patients who have received prior treatment with bipolar androgen therapy (e.g. 
high-dose testosterone, BAT) for castrate-resistant prostate cancer (CRPC); 
permitted if used for hormone-sensitive prostate cancer (HSPC). 
 
Pain due to metastatic prostate cancer requiring opioid therapy. 
 
Patients with an intact prostate AND urinary obstructive symptoms are excluded 
(which includes patients with urinary symptoms from benign prostatic hyperplasia 
(BPH), except where the urinary tract obstruction has been medically or surgically 
resolved. 
 
Patients receiving anticoagulation therapy with Coumadin are not eligible for study. 
[Patients on non-coumadin anticoagulants (Lovenox, Xarelto, etc.) are eligible for 
study. Patients on Coumadin who can be transitioned to Lovenox or Xarelto prior to 
starting study treatments will be eligible] . 
 
Patients with prior history of an arteriovenous thromboembolic event that occurred 
within the last 12 months are excluded.  
 
Patients allergic to sesame seed oil or cottonseed oil are excluded.  
 
Involvement in the planning and/or conduct of the study (applies to both BMS staff 
and/or staff at the study site). 
 
Participation in another clinical study with an investigational product during the 
last 4 weeks/28 days. 
 
Patients should be excluded if they have had prior systemic treatment with an anti-
PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug 
specifically targeting T cell co-stimulation or immune checkpoint pathways (e.g. 
immune checkpoint antagonists). 
 
Evidence of disease in sites or extent that, in the opinion of the investigator, would 
put the patient at risk from therapy with testosterone (e.g. femoral metastases with 
concern over fracture risk, severe and extensive spinal metastases with concern 
over spinal cord compression, extensive liver metastases).  
 
Concurrent use of other anticancer agents or treatments, with the following 
exceptions:  
 
 
Ongoing treatment with LHRH agonists or antagonists, denosumab (Prolia) 
or bisphosphonate (e.g. zoledronic acid) is allowed. Ongoing treatment 
should be kept at a stable schedule; however, if medically required, a change 
of dose, compound, or both is allowed. 
 
Any treatment modalities involving major surgery within 4 weeks prior to the start 
of study treatment. 
 
Symptomatic nodal disease, i.e. scrotal, penile or leg edema (CTCAE ≥ Grade 3). 
 
Patients are excluded if they have active, known brain metastases or leptomeningeal 
metastases. Subjects with brain metastases are eligible if metastases have been 
treated and there is no magnetic resonance imaging (MRI) evidence of progression 
for ≥ 4 weeks after treatment is complete and within 28 days prior to the first dose 
of testosterone administration. There must also be no requirement for 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
32 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone 
equivalents) for ≥ 2 weeks prior to study drug administration. 
 
Patients should be excluded if they have an active, known or suspected autoimmune 
disease (e.g. inflammatory bowel disease, rheumatoid arthritis, autoimmune 
hepatitis, lupus, celiac disease). Subjects are permitted to enroll if they have vitiligo, 
type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only 
requiring hormone replacement, psoriasis not requiring systemic treatment, or 
conditions not expected to recur in the absence of an external trigger. 
 
Patients should be excluded if they have a condition requiring systemic treatment 
with either corticosteroids (> 10 mg/day prednisone equivalents) or other 
immunosuppressive medications within 14 days of study drug administration. 
Inhaled or topical steroids and adrenal replacement doses > 10 mg/day prednisone 
equivalents are permitted in the absence of active autoimmune disease. 
 
Permitted therapies include topical, ocular, intra-articular, intranasal, and 
inhalational corticosteroids (with minimal systemic absorption). Physiologic 
replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day 
prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g. 
contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-
type hypersensitivity reaction caused by contact allergen) is permitted. 
 
As there is potential for hepatic toxicity with Nivolumab, drugs with a 
predisposition to hepatotoxicity should be used with caution in patients treated 
with Nivolumab-containing regimen. 
 
Patients should be excluded if they have a positive test for hepatitis B virus surface 
antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating 
acute or chronic infection. 
 
Patients should be excluded if they have known history of testing positive for human 
immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome 
(AIDS). 
 
History of allergy to study drug components. 
 
History of severe hypersensitivity reaction to any monoclonal antibody. 
 
Other primary tumor (other than CRPC) including hematological malignancy 
present within the last 5 years (except non-melanoma skin cancer or low-grade 
superficial bladder cancer). 
 
Has imminent or established spinal cord compression based on clinical findings 
and/or MRI. 
 
Any other serious illness or medical condition that would, in the opinion of the 
investigator, make this protocol unreasonably hazardous, including, but not limited 
to: 
 
Any uncontrolled major infection. 
 
Cardiac failure NYHA (New York Heart Association) III or IV. 
 
Crohn’s disease or ulcerative colitis. 
 
Bone marrow dysplasia. 
 
Known allergy to any of the compounds under investigation. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
33 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
Unmanageable fecal incontinence. 
 
Persistent toxicities (CTCAE > Grade 2) caused by previous cancer therapy, 
excluding alopecia. 
 
Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant 
systemic disease, or active, uncontrolled infection. Examples include, but are not 
limited to, uncontrolled ventricular arrhythmia, recent (within 6 months) 
myocardial infarction, uncontrolled major seizure disorder, extensive interstitial 
bilateral lung disease, or any psychiatric disorder that prohibits obtaining informed 
consent. 
4. 
PATIENT REGISTRATION AND ENROLLMENT PLAN 
4.1 
Registration Procedure 
After eligibility screening and confirmation that a patient is eligible, patients who are 
selected to participate will be registered with the Lead Center, Johns Hopkins University, 
with their local study site/institution, and if applicable, in the online centralized PCCTC 
database. A record of patients who fail to meet entry criteria (i.e. screen failures) will be 
maintained. Patient registration must be complete before beginning any treatment or study 
activities. A complete, signed study consent is required for registration. 
4.1.1 
Registration at Johns Hopkins University 
Confirm eligibility as defined in Section 3. 
Patient Selection.  
Obtain informed consent, by following procedures in Section 12.3 
 
Written Informed Consent. 
Patient will be entered into the CRMS system and enrolled in the trial.  
4.1.2 
Multicenter/Participating Site Registration 
Central registration for this study will take place at Johns Hopkins University. 
Patient registration at each study site/institution will be conducted according to the 
institution’s established policies. Before registration, patients will be asked to sign 
and date an Institutional Review Board (IRB)-approved consent form. Patients must 
be registered with their local site/institution and also with the Lead Site before 
beginning any treatment or study activities. 
 
 
5. 
TREATMENT/INTERVENTION PLAN 
 
The following assessments and procedures will occur during the study. A schedule of 
assessments is provided in Table 2. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
34 of 97 
 COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Table 2. Study Calendar 
  
Screening 
                                                      Study Period 
On Treatment Assessments                     
(Every 28 days) 
BAT Alone 
On Treatment Assessments    
(Every 28 days) 
Nivolumab + BAT  
End of 
Treatment 
Visit 
Off study 
follow‐up 
 
Survival 
follow‐up 
 
Day           
-28 to -1 
C1D1    
(±5 d) 
JHU only 
 
C1D4 
(±5 d) 
 
 
C2D1      
(±5 d) 
C3D1       
(±5 d) 
C4D1          
(±5 d)c 
CnD1           
(±5 d) 
28 days 
after last 
dose 
 
 
 
(±5 d)c 
Every 28 
days e / 
100 days 
after last 
dose 
 
(±5 d) 
Up to 1 year 
after last 
dose or AE 
resolution 
datee 
 
(Q6mo.) 
Informed Consent 
Xa 
  
 
  
  
  
  
  
 
Demographics 
X 
  
 
  
  
  
  
  
 
Complete Medical History 
X 
  
 
  
  
  
  
  
 
EKG 
Xk 
  
 
  
  
  
  
 
Testosterone cypionate 
  
X 
 
X 
X 
X 
X 
  
 
Nivolumab 
  
  
 
  
  
X 
X 
  
 
Focused Medical History 
  
X 
 
X 
X 
X 
X 
X 
 
Physical Exam 
Xl 
Xl 
 
Xl 
Xl 
Xl 
Xl 
Xl 
 
Vital Signs (P, BP, RR, T) 
Xl 
Xl 
 
Xl 
Xl 
Xl 
Xl 
Xl 
 
Height 
Xl 
  
 
  
  
  
  
  
 
Weight 
Xl 
Xl 
 
Xl 
Xl 
Xl 
Xl 
Xl 
 
ECOG Performance Status 
(ECOG) 
X 
  
 
X 
X 
X 
X 
X 
 
Toxicity Assessment 
X 
  
 
X 
X 
X 
X 
X 
 
Concomitant Medications 
X 
X 
 
X 
X 
X 
X 
X 
 
 
CBC w/ Diff 
X 
Xg 
 
X 
X 
X 
X 
X 
 
 
CMP 
X 
Xg 
 
X 
X 
X 
X 
X 
 
 
PSA 
X 
Xg 
 
X 
X 
X 
X 
X 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
35 of 97 
 COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Serum Testosterone 
X 
Xg 
X 
X 
X 
X 
X 
X 
 
 
Serum Amylase/Lipase/ 
CK; TSH w/ Reflex T3, T4 
X 
  
  
  
 
X 
X 
X 
 
 
Hepatitis B/C; PTT, 
PT/INR; Urinalysis 
X 
  
  
  
 
  
  
  
 
 
Radiologic Tests 
Xb 
  
  
  
 
Xbc 
Xb 
Xbc 
 
 
Core Tumor Biopsy 
Xf 
  
  
  
 
Xf 
  
Xf 
 
 
Rectal Swab  
 
  Xi  
  
  
 
 Xi 
 Xi 
  
 
 
Germline DNA Testing 
 
 Xh 
  
  
 
 
 
  
 
 
Plasma for MANAs/TAAs 
 
Xd 
  
  
 
Xd 
 
Xd 
 
 
Plasma for Chemokines 
 
Xj 
Xj 
Xj 
 
 
Xj 
 
 
 
Adverse Events 
  
  
 
X 
X  
X 
X 
X 
Xe 
 
Survival Contact 
 
 
 
 
 
 
 
 
Xe 
Abbreviations: CBC, complete blood count; CT, computerized tomography; MRI, magnetic resonance imaging; PSA, prostate-specific antigen; CK, creatine kinase; TSH, thyroid 
stimulating hormone 
 
a 
Informed consent should be obtained within 4 weeks (28 days) of study start date (C1D1).  
b 
Radiographic evaluations (CT C/A/P) and NM Bone Scan every 3 months while enrolled in the study) are needed within 4 weeks of the screening visit; if previously performed within the last 4 
weeks they do not need to be repeated. CT C/A/P and NM Bone Scan are to be performed at the End of Treatment (EOT) visit if they have not been performed within the prior month.  
c 
For visits C4D1 and EOT only, the window for radiographic evaluations will be extended to 2 weeks before the visit occurs to account for biopsy scheduling availability. 
d 
Plasma for MANAs/TAAs assay will be drawn at C1D1, C4D1, and at progression (EOT) for JHU patients ONLY. 
e 
Subjects will be followed after withdrawal of BAT +/- Nivolumab therapy due to toxicity, monthly until toxicities resolve to grade ≤ 1. Otherwise, subjects will be followed at 100 days after last 
dose for AE reassessment. Survival follow-up will continue for up to 1 year through telephone contact every 6 months, to begin after the 100-day follow-up contact or from the AE resolution date 
if it exceeds the 100 day follow-up timepoint. 
f 
MANDATORY core tumor biopsy performed during the Screening period (prior to C1D1) (Day -28 to -1) and on C4D1 (+/- 7 days). An OPTIONAL tumor biopsy will be performed at the End of 
Treatment visit (+/- 7 days).  
g  
Labs do not need to be repeated if done within 7 days of screening. 
h  
Germline DNA testing per standard of care practice is optional. To be submitted after obtaining informed consent and prior to C2D1. 
i        Rectal Swabs to be performed before treatment with testosterone (C1D1), prior to starting Nivolumab (C4D1), and after 3 cycles of Nivolumab (C7D1) for JHU patients ONLY. 
j        Plasma sample for Chemokines analysis (optional) will be obtained at C1D1 prior to the first injection of BAT, 3 hours after the first injection of BAT, C1D4, C2D1, and C7D1 for JHU patients ONLY. 
k       EKG’s must be collected within 14 days of receiving the first study treatment. 
l       Physical exam (including vital signs/height/weight) may be missed if not clinically indicated or in the event of a telemedicine visit. In order to minimize the need for research-only in-person visits, 
telemedicine visits may be substituted for in-person clinical trial visits or portions of clinical trial visits where determined to be appropriate and where determined by the investigator not to 
increase the participants risks. Prior to initiating telemedicine for study visits the study team will explain to the participant, what a telemedicine visit entails and confirm that the study participant 
is in agreement and able to proceed with this method. Telemedicine acknowledgement will be obtained in accordance with the Guidance for Use of Telemedicine in Research. In the event 
telemedicine is not deemed feasible, the study visit will proceed as an in-person visit. Telemedicine visits will be conducted using HIPAA compliant method approved by the Health System and 
within licensing restrictions. 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins 
 
 
36 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
5.1 
Screening Assessment (Day ‐28 to Day ‐1) 
Before initiating any screening activities, the scope of the study should be explained to each 
patient. Patients should be advised of any known risks inherent in the planned procedures, 
any alternative treatment options, their right to withdraw from the study at any time for 
any reason, and their right to privacy. After this explanation, patients should be asked to 
sign and date an IRB-approved informed consent that meets the requirements of the Code 
of Federal Regulations (Federal Register Vol. 46, No. 17, January 27, 1981, part 50).
The screening visit will determine patient eligibility according to the inclusion and 
exclusion criteria (Sections 3.3 Inclusion Criteria & 3.4 Exclusion Criteria). The following 
assessments will be performed at this visit:  
 
Obtain informed consent and research authorization. 
 
Record demographics (including age) and medical history (including 
prior treatment for prostate carcinoma). 
 
Conduct physical exam (including vital signs, height/weight).  The 
physical exam may be missed if screening visit is taking place over 
telemedicine. 
 
Obtain histologic and radiologic confirmation of disease. If radiographic 
studies have not been performed in prior 4 weeks of the screening visit, 
they must be obtained as part of screening. 
 
Obtain history regarding prior treatment history for prostate cancer 
(including history of ADT, history of radiation therapy, or other local 
therapy). 
 
Perform laboratory tests (Complete blood count w/ Diff, PSA, 
Comprehensive metabolic panel, urinalysis, PT/INR, PTT, serum 
testosterone, TSH with reflexive T3, T4 testing, serum Creatine kinase 
(CK), serum amylase/lipase, and Hepatitis B/C panel). 
 
Assess performance status (ECOG). (Appendix B). 
 
Perform 12-lead EKG. ECGs are required within 14 days prior to 
starting study treatment and when clinically indicated. 
 
Twelve-lead ECGs will be obtained after the patient has been 
rested in a supine position for at least 5 minutes in each case.  
The Investigator or designated physician will review the paper 
copies of each of the timed 12-lead ECGs on each of the study 
days when they are collected. 
 
ECGs will be recorded at 25 mm/sec.  All ECGs should be 
assessed by the Investigator as to whether they are clinically 
significantly abnormal or not clinically significantly abnormal.  
If there is a clinically significant abnormal finding, the 
Investigator will record it as an AE on the eCRF.  The original 
ECG traces must be stored in the patient medical record as 
source data. 
 
Determine suitability for Testosterone + Nivolumab. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins 
 
 
37 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
Obtain image-guided biopsy of a site of disease (i.e. soft tissue, lymph 
node) – further described in section 5.1.1. 
 
Discuss concurrent medications.  
 
Provide instructions for obtaining a CLIA-certified laboratory (i.e. 
COLOR genomics) kit for germline DNA testing per standard of care 
practice (Optional). 
 
Relevant information should be documented. The institutional registration should be 
finalized, and appropriate documents (i.e. signed informed consent and supporting source 
documentation for eligibility questions) emailed to the Lead site. 
 
Information for patients who do not meet the eligibility criteria to participate in this study 
(i.e. screening failures) should be captured in the CRMS database at the screening 
assessment. 
 
5.1.1 
Surgical Procedures 
A core needle biopsy of a site of disease (soft tissue, lymph node) will be performed 
during the Screening period (prior to C1D1). Patients will be referred to their 
respective biopsy service for an image-guided core biopsy. At least 4 standard core 
biopsies should be attempted to be obtained from the site (soft tissue, lymph node). 
Fine needle aspiration is unlikely to yield adequate tumor tissue for molecular 
analysis, and should only be attempted when core biopsy is not feasible.  The unique 
subject number given by the Lead site during registration should be used to identify 
the biopsy samples to protect the subject’s identity.  
For each biopsy timepoint, ≥ 4 fresh cores will be collected from the same site of 
disease chosen during the Screening period (prior to C1D1); ≥ 2 fresh cores will be 
collected for immediate flash-freezing in liquid nitrogen and ≥ 2 cores will be 
formalin-fixed and paraffin-embedded. For soft-tissue biopsies, 18-gauge core 
biopsy needles are recommended. 
To minimize tissue autolysis, a dedicated tissue technician should be appointed and 
called/paged to the biopsy room to initiate processing steps including FFPE 
preparation, which should be done within 30 minutes of biopsy collection, and the 
flash-freezing of the other designated cores with liquid nitrogen. FFPE specimens 
should be processed according to standard institutional FFPE procedures. All 
samples will be sent to the De Marzo Laboratory for analysis. 
Note. If site(s) do not have the capability to perform flash-freezing of tumor tissue 
cores with liquid nitrogen, all available tumor tissue core specimens should be 
prepared and processed according to standard institutional FFPE procedures. 
 
5.1.1.1 Potential Biopsy Complications 
Potential complications of a research biopsy include: infection, bleeding, and 
pain at the biopsy site. 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
38 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
5.2 
Testosterone Lead‐in Period (Day 1 of each 28 day cycle +/‐ 5 days, (C1D1, C2D1, 
 
C3D1)) 
Patients will be seen on Day 1 of each cycle of testosterone (consisting of 28 days, +/- 5 
days).  The following assessments will be performed at each visit:  
 
Conduct physical exam (including vital signs, weight).  The physical 
exam may be missed if visit is taking place over telemedicine. 
 
Obtain any medical history changes from prior assessment. 
 
Assess performance status (ECOG). (Appendix B). 
 
Review concurrent medications.   
 
Confirm germline DNA sample submitted per standard of care practice, 
if applicable (To be submitted prior to C2D1). 
 
Obtain Rectal swab for microbiome analysis for JHU patients ONLY. 
5.2.1 
Clinical and Laboratory Assessments 
On Day 1 of each cycle, patients will have a non-fasting blood draw for the following 
values: (Repeat labs are not needed on C1D1 if within 7 days of screening values.) 
 
CBC w/ Diff 
 
Comprehensive metabolic panel 
 
PSA 
 
Serum Testosterone 
 
MANAs/TAAs assay blood draw (100mL; C1D1 only) for JHU patients 
ONLY 
 
Chemokines plasma blood draw (10mL; C1D1 predose, 3 hours after 
first testosterone injection, C1D4, C2D1) for JHU patients ONLY 
(Optional). 
Laboratory Safety Assessments: 
Full hematology assessments for safety (hemoglobin, red blood cells [RBC], 
platelets, mean cell volume [MCV], mean cell hemoglobin concentration [MCHC], 
mean cell hemoglobin [MCH], white blood cells [WBC], absolute differential white 
cell count (neutrophils, lymphocytes, monocytes, eosinophils and basophils) and 
absolute neutrophil count or segmented neutrophil count and Band forms should be 
performed at each visit and when clinically indicated.  If absolute differentials not 
available, will check % differentials. Coagulation [activated partial thromboplastin 
time (APTT) and international normalized ratio (INR)] will be performed at baseline 
and if clinically indicated. 
Biochemistry assessments for safety (sodium, potassium, calcium, glucose, 
creatinine, total bilirubin, alkaline phosphatase [ALP], aspartate transaminase 
[AST], alanine transaminase [ALT], urea or blood urea nitrogen [BUN], total protein, 
albumin. 
Urinalysis should be performed at baseline and then only if clinically indicated. 
Microscopic analysis should be performed by the hospital’s local laboratory if 
required. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
39 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
These tests will be performed by the hospital’s local laboratory.  Additional analyses 
may be performed if clinically indicated. 
Any clinically significant abnormal laboratory values should be repeated as clinically 
indicated and recorded on the eCRF. 
In case a subject shows an AST or ALT ≥ 3xULN or total bilirubin ≥ 2xULN, please 
refer to Appendix F “Actions required in cases of combined increase of 
Aminotransferase and Total Bilirubin – Hy’s Law”, for further instructions. 
5.2.3 
Safety Assessments 
Adverse events (AEs) will be monitored at each scheduled visit and throughout the 
study. Toxicity will be assessed using the most recent National Cancer Institute 
(NCI) guidance: the most recent version of Common Terminology Criteria for 
Adverse Events (CTCAE).  
5.3 
Testosterone/Nivolumab Combination Period (Day 1 of each 28 day cycle +/‐ 5 days, 
 
(C4D1, C5D1, CnD1,  continuous)) 
Patients will be seen on D1 of each cycle of Testosterone/Nivolumab (consisting of 28 days, 
+/- 5 days).  The following assessments will be performed at each visit:  
 
Conduct physical exam (including vital signs, weight).  The physical 
exam may be missed if visit is taking place over telemedicine. 
 
Obtain any medical history changes from prior assessment. 
 
Assess performance status (ECOG). (Appendix B). 
 
Review concurrent medications.  
5.3.1 
Clinical and Laboratory Assessments 
On Day 1 of each cycle (beginning C4D1), patients will have a non-fasting blood 
draw for the following values:   
 
CBC w/ Diff 
 
Comprehensive metabolic panel 
 
PSA  
 
Serum Testosterone 
 
TSH w/ reflexive T3, T4 
 
Serum Amylase/Lipase 
 
Serum Creatine kinase (CK) 
 
MANAs/TAAs assay blood draw (C4D1, End of Treatment) for JHU patients 
ONLY 
 
Rectal swab will be obtained prior to C4D1 and C7D1 for JHU patients ONLY 
 
Chemokines plasma blood draw (10mL; C7D1) for JHU patients ONLY 
(Optional) 
Every 3 cycles, patients will have radiographic studies beginning C4D1: 
 
CT Chest, Abdomen, and Pelvis with contrast. 
 
NM Bone scan. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
40 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Note: For visits C4D1 and EOT only, the window for obtaining radiographic 
evaluations will be extended to 2 weeks before the visit occurs to account for biopsy 
scheduling availability. 
5.3.2 
Surgical Procedures 
A core needle biopsy will be performed on C4D1 (+/- 7 days) at the same site of     
disease previously biopsied during the Screening period. This biopsy is considered 
mandatory. However, patients can remain on study if biopsy is refused. Further 
description of this biopsy can be found in section 5.1.1. 
5.4 End of Treatment/Treatment Discontinuation Visit (28 days after last dose +/‐ 5 days) 
 
Conduct physical exam (including vital signs, weight).  The physical exam may be missed if 
visit is taking place over telemedicine. 
 
Assess performance status (ECOG). (Appendix B). 
 
Review concurrent medications. 
 
Assess AEs. 
 
If patient is discontinuing participation in study, perform radiographic tests: CT C/A/P and 
NM Bone Scan (if not performed within the prior month). 
 
The following non-fasting blood draw will include: 
 
CBC w/ Diff 
 
Comprehensive metabolic panel 
 
PSA  
 
Serum Testosterone 
 
TSH w/ reflexive T3, T4 
 
Serum Amylase/Lipase 
 
Serum Creatine kinase (CK) 
 
MANAs/TAAs assay blood draw (if not done within the prior 90 days) 
for JHU patients ONLY 
5.4.1 
Surgical Procedures 
A core needle biopsy will be performed at progression (EOT) (+/- 7 days) at the 
same site of disease previously biopsied during the Screening period. This biopsy is 
considered optional. Further description of this biopsy can be found in section 5.1.1. 
 
5.5 
Follow‐up (Every 28 days while active AEs/100 days after last dose & Survival status 
+/‐ 5 days) 
Patients that received Nivolumab and discontinue due to progression, will be followed and 
contacted at 100 days after last dose.  
 
Patients that have discontinued the study due to AEs will be followed every 28 days 
(monthly) beyond the end of treatment (EOT) visit. They will be followed until the AE has 
either resolved or stabilized (Grade ≤ 1). If the event resolves or stabilizes before they reach 
100 days after last dose, they will be contacted at the 100 day timepoint. Reasons for 
premature withdrawal should be determined and noted.  
 
To be performed at each contact will be: 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
41 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
Reassess AEs. 
 
Following completion of the 100 day follow-up OR the resolution/stabilization of the AE(s) 
responsible for premature withdrawal (if beyond 100 days after last dose), patients will be 
followed for overall survival every 6 months for 1 year.  
 
To be performed at each contact will be: 
 
 
Reassess for survival. 
 
5.6 
Correlative/Special Studies 
5.6.1. DNA Sequencing 
FFPE biopsy tissue (collected during the Screening period) will be sent to Foundation 
Medicine for next generation sequencing, based upon their commercially available platform.   
 
5.6.2. PD‐1, PD‐L1, FOXP3, CD4, CD8, γH2AX, RAD51, 53BP1 Protein Levels 
A sample of biopsy (from each biopsy done on study) will be sent to the De Marzo 
Laboratory for analysis. 
 
5.6.3. Whole Exome Sequencing  
Flash frozen biopsy tissue collected from the Screening period/C4D1/ progression (EOT) 
biopsies will be sent to the De Marzo Laboratory for whole exome sequencing in 
collaboration with the Next Generation Sequencing Core Lab to be performed in concert 
with the MANAs/TAAs assays. 
 
5.6.4. MANAs/TAAs Assay 
Plasma will be obtained at C1D1, C4D1, and at progression (EOT). The MANAs/TAAs assay 
will be performed by the Immune Processing Core Lab (Appendix C). 
 
5.6.6.  Chemokines Analysis 
Plasma will be obtained prior to the first BAT injection on C1D1, 3 hours and 3 days (C1D4) 
after the first testosterone injection, C2D1, and C7D1. Samples will be processed and stored 
in the Denmeade Laboratory at Johns Hopkins. Analysis will be performed by the Immune 
Processing Core Lab. 
 
 
6. 
Study Drugs 
6.1 
Description of Treatments 
The drugs to be tested in this clinical protocol are Testosterone cypionate and Nivolumab.    
Nivolumab will be supplied by Bristol-Myers Squibb, Co. 
6.2 
Administration, Supply, and Storage 
Nivolumab will be dosed at 480mg IV over a 30 minute period every 4 weeks (+/- 5 days) 
beginning on C4D1. Testosterone cypionate will be dosed at 400mg IM every 4 weeks (+/- 5 
days) beginning on C1D1. Treatment will be administered on an outpatient basis.  
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
42 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Nivolumab: 
 
PRODUCT INFORMATION TABLE: Please also see Nivolumab Investigator Brochure. 
Table 
Product Description 
Product 
Description and 
Dosage Form 
Potency 
Primary 
Packaging
(Volume) 
Secondary 
Packaging 
(Qty)/ 
Label Type 
Appearance 
Storage 
Conditions 
(per label) 
Nivolumab BMS-
936558-01 
Solution for 
Injection 
100 mg  
(10 mg/mL) 
10 mL vial
5 vials per 
carton/Open-
label 
Clear to opalescent 
colorless to pale 
yellow liquid. May 
contain particles. 
2 to 8°C. Protect 
form light and 
freezing. 
*Nivolumab may be labeled as BMS-936558-01 Solution for Injection 
 
If stored in a glass front refrigerator, vials should be stored in the carton. Recommended 
safety measures for preparation and handling of Nivolumab include laboratory coats and 
gloves. 
For additional details on prepared drug storage and use time of Nivolumab under room 
temperature/light and refrigeration, please refer to the BMS-936558 (Nivolumab) 
Investigator Brochure section for “Recommended Storage and Use Conditions”.  
 
Testosterone cypionate 
Testosterone cypionate injection is for intramuscular use only. It should not be given intravenously. 
Intramuscular injections should be given deep in the gluteal muscle.  
Testosterone will be used in the commercially available formulation, it will be purchased by the 
participant’s site pharmacy; the cost will be covered by the study and will be provided to the 
patient at no charge.  
Vials should be stored at controlled room temperature 20°C to 25°C (68°F to 77°F) [see USP]. 
Protect from light. Use carton to protect contents from light until used. Warming and rotating the 
vial between the palms of the hands will redissolve any crystals that may have formed during 
storage at low temperatures.  
7 
DOSE ADJUSTMENT AND DELAY, TREATMENT DISCONTINUATION, 
 
WITHDRAWAL, AND TERMINATION CRITERIA 
 
7.1 
Dosing and Dose Modifications 
 
7.1.1 Dosing 
Testosterone cypionate will be given at a dose of 400mg IM every 28 days (4 weeks) 
approximately (+/- 5 days) beginning on C1D1 until progression or end of study. 
Nivolumab 480mg will administered intravenously over a 30 minute period every 4 weeks 
(+/- 5 days) beginning on C4D1 until progression or end of study.   
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
43 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
7.1.2 Dose Modifications 
There will be no dose modifications permitted. Dose reductions or dose escalations are not 
permitted. 
7.2        Dose Delay and Treatment Discontinuation 
Dose delay criteria apply for all drug-related adverse events (regardless of whether or not 
the event is attributed to Nivolumab, Testosterone, or both). All study drugs must be 
delayed until treatment can resume. 
7.3 
Dose Delay Criteria  
Nivolumab and Testosterone administration should be delayed for the following: 
 
Any Grade ≥ 2 non-skin, drug-related adverse event, with the following exceptions: 
 
Grade 2 drug-related fatigue or laboratory abnormalities do not require a treatment 
delay. 
 
Any Grade 3 skin, drug-related adverse event. 
 
Any Grade 3 drug-related laboratory abnormality, with the following exceptions for AST, 
ALT, or total bilirubin: 
 
Delay dosing for drug-related AST, ALT, or total bilirubin grade ൒ 2 toxicity. 
 
Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical 
manifestations of pancreatitis do not require a dose delay.  
 
Grade 3 lymphopenia does not require a dose delay. 
 
Any adverse event, laboratory abnormality, or intercurrent illness, which, in the judgment 
of the investigator, warrants delaying the dose of study medication. 
Because of the potential for clinically meaningful Nivolumab-related AEs requiring early 
recognition and prompt intervention, management algorithms have been developed for 
suspected pulmonary toxicity, GI, hepatotoxicity, endocrinopathy, skin toxicity, neurological 
toxicity and renal toxicity. The recommendations are to follow the Nivolumab IB adverse 
event algorithm (Appendix A). 
7.4  
Criteria to Resume Treatment 
Missed doses of Nivolumab and/or Testosterone should be administered when subject 
meets criteria to resume treatment. If a Testosterone and Nivolumab dose has been 
missed, the subject should wait until the next scheduled dosing date following the 
originally planned dosing schedule that is consistent with the study calendar. 
 
Subjects  may  resume  treatment  with  study  drug  when  the  drug-related AE(s)  
resolve to Grade ≤ 1 or baseline value, with the following exceptions: 
 
Subjects may resume treatment in the presence of Grade 2 fatigue. 
 
Subjects who have not experienced a Grade 3 drug-related skin AE may resume 
treatment in the presence of Grade 2 skin toxicity. 
 
For subjects with Grade 2 AST, ALT, or total bilirubin elevations, dosing may resume 
when laboratory values return to baseline and management with corticosteroids, if 
needed, is complete. 
 
Subjects with combined Grade 2 AST/ALT AND total bilirubin values meeting 
discontinuation parameters should have treatment permanently discontinued. 
 
Drug-related diarrhea, or colitis, must have resolved to baseline before treatment is 
resumed.  
 
Subjects with persistent Grade 1 pneumonitis after completion of a steroid taper over at 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
44 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
least 1 month may be eligible for retreatment if discussed with and approved by the 
investigator. 
 
Drug-related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment. 
 
If treatment is delayed > 10 weeks, the subject must be permanently discontinued from 
study therapy. 
 
If the subject is unable to resume both Nivolumab and Testosterone, permanent 
discontinuation is required. 
 
7.5         Discontinuation Criteria 
Treatment with Nivolumab and Testosterone should be permanently discontinued for any 
of the following: 
     Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not respond 
to topical therapy and does not improve to Grade 1 severity within the re-treatment period 
OR requires systemic treatment. 
     Any Grade 3 non-skin, drug-related adverse event lasting > 7 days, with the following 
exceptions for drug-related laboratory abnormalities, uveitis, pneumonitis, bronchospasm, 
diarrhea, colitis, neurologic toxicity, hypersensitivity reactions, and infusion reactions: 
 
Grade 3 drug-related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, 
neurologic toxicity, hypersensitivity reaction, or infusion reaction of any duration 
requires discontinuation. 
 
Grade 3 drug-related endocrinopathies adequately controlled with only physiologic 
hormone replacement do not require discontinuation, except for Grade 3 adrenal 
insufficiency which requires permanent discontinuation. 
 
Grade 3 drug-related laboratory abnormalities do not require treatment 
discontinuation except: 
 
Grade 3 drug-related thrombocytopenia > 7 days or associated with 
bleeding requires discontinuation. 
 
Any drug-related liver  function  test  (LFT)  abnormality that  meets  the  
following criteria require discontinuation: 
 
Grade > 3 drug-related AST, ALT, or total bilirubin requires 
discontinuation. 
 
Concurrent AST or ALT > 3xULN and total bilirubin > 2xULN. 
     Any Grade 4 drug-related adverse event or laboratory abnormality, except for the 
following events which do not require discontinuation: 
 
Grade 4 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis.  
 
Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplementation/appropriate management   
within 72 hours of their onset. 
 
Grade 4 neutropenia < 7 days. 
 
Grade 4 lymphopenia or leukopenia. 
 
Grade 4 drug-related endocrinopathy AEs, such as, hyper- or hypothyroidism, or 
glucose intolerance, that resolve or are adequately controlled with physiologic 
hormone replacement (corticosteroids, thyroid hormones) or glucose-controlling 
agents, respectively, may not require discontinuation after discussion with and 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
45 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
approval from the investigator. Grade 4 drug-related adrenal insufficiency or 
hypophysitis requires discontinuation regardless of control with hormone 
replacement. 
    Any dosing interruption lasting > 10 weeks unless the investigator is consulted and agrees 
with the rationale for resuming therapy after a delay > 10 weeks. Note that tumor 
assessments should continue as per protocol even if dosing is interrupted. 
   Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment 
of the Investigator, presents a substantial clinical risk to the subject with continued 
Nivolumab dosing. 
7.6 
Treatment of Nivolumab‐Related Infusion Reactions 
Since Nivolumab contains only human immunoglobulin protein sequences, each is 
unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, 
if such a reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, 
pruritus, arthralgias, hypo- or hypertension, bronchospasm, or other symptoms. Infusion 
reactions should be graded according to the most current NCI CTCAE guidelines. 
Treatment recommendations are provided below and may be modified based on local 
treatment standards and guidelines as appropriate: 
For Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention 
not indicated) 
Remain at bedside and monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 
mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 
minutes before additional nivolumab administrations. 
For Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [e.g. antihistamines, non-steroidal anti-
inflammatory drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic 
medications indicated for up to 24 hours). 
Stop the Nivolumab infusion, begin an IV infusion of normal saline, and treat the subject 
with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until resolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of the original infusion rate when 
symptoms resolve; if no further complications ensue after 30 minutes, the rate may be 
increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur 
then no further Nivolumab will be administered at that visit. Administer diphenhydramine 
50 mg IV, and remain at bedside and monitor the subject until resolution of symptoms. 
The amount of study drug infused must be recorded on the electronic case report form 
(eCRF). The following prophylactic premedications are recommended for future infusions: 
diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen) should be administered at least 30 minutes before additional Nivolumab 
or administrations. If necessary, corticosteroids (recommended dose: up to 25 mg of IV 
hydrocortisone or equivalent) may be used. 
For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [i.e. not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of 
symptoms following initial improvement; hospitalization indicated for other clinical 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
46 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
sequelae [e.g. renal impairment, pulmonary infiltrates]). Grade 4: (life-threatening; pressor 
or ventilatory support indicated). 
Immediately discontinue infusion of Nivolumab. Begin an IV infusion of normal saline, and 
treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 
1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution 
injected  slowly  for  IV  administration,  and/or  diphenhydramine  50  mg  IV  with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored 
until the investigator is comfortable that the symptoms will not recur. Nivolumab will be 
permanently discontinued. Investigators should follow their institutional guidelines for the 
treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from 
symptoms. In the case of late-occurring hypersensitivity symptoms (e.g. appearance of a 
localized or generalized pruritis within 1 week after treatment), symptomatic treatment 
may be given (e.g. oral antihistamine, or corticosteroids). 
7.7   
Treatment Beyond Disease Progression 
Accumulating evidence indicates a minority of subjects treated with immunotherapy may 
derive clinical benefit despite initial evidence of PD, as described by irRECIST criteria 
(Nishino et al, Clin Cancer Res; 19(14) July 15, 2013). Subjects will be permitted to continue 
treatment beyond initial investigator-assessed progression without reconsent as long as 
they meet the following criteria: 
 
  Investigator-assessed clinical benefit and subject is tolerating study drug. 
  The assessment of clinical benefit should take into account whether the subject is clinically  
deteriorating and unlikely to receive further benefit from continued treatment. 
  Subjects should discontinue study therapy upon evidence of further progression, defined as 
an additional 10% or greater increase in tumor burden volume from time of initial 
progression (including all target lesions and new measurable lesions). 
  Per irRECIST criteria, new lesions are considered measurable at the time of initial 
progression if the longest diameter is at least 10 mm by CT scan (except for pathological 
lymph nodes, which must have a short axis of at least 15 mm). Any new lesion considered 
non-measurable at the time of initial progression may become measurable and therefore 
included in the tumor burden measurement if the longest diameter increases to at least 10 
mm by CT scan (except for pathological lymph nodes, which must have an increase in short 
axis to at least 15 mm). In situations where the relative increase in total tumor burden by 
10% is solely due to inclusion of new lesions which become measurable, these new lesions 
must demonstrate an absolute increase of at least 5 mm.  Further bone disease progression is 
defined as additional two or more new bone lesions noted on bone scans compared to the 
time of PCWG3-defined progression of bone disease. 
 
 
Testosterone Only Phase: 
During the Testostone-only lead-in phase (12 weeks), patients may experience PSA 
progression in the presence or absence of radiographic progression. Patients will be allowed 
to remain on study in the following circumstances: 
 
PSA Progression Only: 
In the setting of a rising PSA (including patients with PSA progression [PCWG3 criteria]) in the 
absence of radiographic progression (RECIST 1.1 Criteria), patients without clinical symptoms 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
47 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
of disease progression will be allowed to remain on study.  If the patient is not deriving clinical 
benefit, patients may be removed from the study at the discretion of the treating physician. 
 
Radiographic Progression: 
Patients with radiographic progression (per RECIST 1.1 Criteria) determined on post-
testosterone, restaging imaging may remain on study except in ANY of the following 
circumstances: 
 
Patient is not deriving clinical benefit as determined by the treating physician 
 
Development of symptoms of clinical progression (any of the below): 
 
New bony pain. 
 
Risk of impending fracture. 
 
Pending spinal cord compression. 
 
Obstructive urinary symptoms. 
 
Decline in performance status from baseline assessment. 
 
Development of new liver or brain metastases. 
For patients that continue on study after radiographic progression (as documented on initial 
imaging), restaging must occur between 6-7 weeks +/- 5 days from prior imaging. Subjects 
should discontinue study therapy upon evidence of further progression, defined as an 
additional 10% or greater increase in tumor burden volume from time of initial progression 
(i.e. post testosterone only imaging).  Subsequent imaging will continue as per protocol and 
irRECIST criteria should be used to assess further progression of the Testosterone + 
Nivolumab combination. 
 
7.8       Immunotherapy Adverse Event Management 
Because  of  the  potential  for  clinically  meaningful  Nivolumab-related AEs requiring early 
recognition and prompt intervention, management algorithms have been developed for 
suspected pulmonary toxicity, GI toxicity, hepatotoxicity, endocrinopathy, skin toxicity, 
neurological toxicity, and renal toxicity (Nivolumab IB). 
These adverse event management algorithms are included in Appendix A. 
7.9 
Removal of Subjects from the Study, Therapy Assessment 
7.9.1 
Subject Withdrawal 
Single subject termination is by definition when the patient is withdrawn or when 
the patient has died.  The study termination page in the eCRF must be completed. 
The Investigator also has the right to withdraw subjects from the study in the event 
of: 
 
Occurrence of an exclusion criterion, which is clinically relevant and affects the 
subject’s safety, and discontinuation is considered necessary by the Investigator 
and/or the Sponsor. 
 
Therapeutic failure requiring urgent additional medication (if applicable) 
 
Occurrence of AEs, if discontinuation of study medication is considered 
necessary by the Investigator and/or Subject (if applicable). 
 
Intake of non-permitted concomitant medication as defined in Appendix A 
where the predefined consequence is withdrawal from the study.  

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
48 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
Progression of disease (subjects will only come off study after meeting PCWG3 
criteria for radiographic progression and not for PSA) except as described in 
Section 7.7. 
 
Lack of subject compliance. 
 
Protocol violation. 
 
7.10     Treatment Compliance 
Trained medical personnel will administer Nivolumab and dispense other study 
medications. Treatment compliance will be monitored by drug accountability, as well as by 
recording administration of all medications in the CRF. The date and the exact dosage 
amount given at each infusion will be recorded. Any missed doses will be recorded. In case 
the treatment has to be interrupted during an infusion and the dosing is not resumed, the 
medical personnel should evaluate the percentage of dose received by the patient and 
document it in the patient record. Any reason for non-compliance should also be 
documented. 
 
7.11      Destruction of Study Drug 
Investigator drug destruction is allowed provided the following minimal standards are met: 
• On-site disposal practices must not expose humans to risks from the drug. 
• On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances. 
• Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the Sponsor SOPs and a copy provided to BMS upon request. 
• Records are maintained that allow for traceability of each container, including the date 
disposed of, quantity disposed, and identification of the person disposing the containers. 
The method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal 
vendor must be documented. 
• Accountability and disposal records are complete, up-to-date, and available for BMS to 
review throughout the clinical trial period as per the study agreement. A copy of the drug 
destruction certificate should be maintained for provision to BMS at the end of the study. 
If conditions for destruction cannot be met, please contact BMS.  
It is the Investigator’s responsibility to arrange for disposal of all empty containers, 
provided that procedures for proper disposal have been established according to applicable 
federal, state, local, and institutional guidelines and procedures, and provided that 
appropriate records of disposal are kept. 
7.12   Return of Study Drug 
It is the Investigator’s responsibility to arrange for destruction of drug upon completion or 
termination of the study and disposal of all empty containers, provided that procedures for 
proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal 
are kept. 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
49 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
8. 
ADVERSE EVENTS 
 
8.1 
Definitions 
8.1.1 
Adverse Event (AE) 
 
 
An AE is defined as any untoward medical occurrence in a patient administered a 
medicinal product that does not necessarily have a causal relationship with this 
treatment. An AE can, therefore, be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of an investigational product, whether or not related to the investigational 
medicinal product. This includes an exacerbation of pre-existing conditions or 
events, intercurrent illnesses, drug interaction, or the significant worsening of the 
indication under investigation that is not recorded elsewhere on the eCRF under 
specific efficacy assessments. Anticipated fluctuations of pre-existing conditions, 
including the disease under study, that do not represent a clinically significant 
exacerbation or worsening are not considered AEs. 
 
It is the responsibility of the Investigator to document all AEs that occur during the 
study. AEs should be elicited by asking the patient a non-leading question (e.g. 
“Have you experienced any new or changed symptoms since we last asked/since 
your last visit?”). The existence of an AE may be concluded from a spontaneous 
report of the patient; from the physical examination; or from special tests such as 
the ECG, laboratory assessments, or other study-specified procedure (source of AE). 
Symptoms reported spontaneously by the patient during the physical examination 
would also qualify as an AE (and hence documented on the AE eCRF, not on the 
physical examination eCRF, which is reserved for physical signs or findings). 
 
8.1.2 
Serious Adverse Event (SAE) 
An SAE is any untoward medical occurrence that occurs at any dose (or, occurs after 
informed consent is given and prior to dosing if the SAE is related to a study 
procedure) that: 
 
Results in death. Any event resulting in death during the reporting period (from 
date of first dose of study drug through 100 days after last dose) must be treated as 
an SAE and reported as such. An event related to a study procedure that occurs after 
informed consent, but prior to dosing that results in death must also be reported as 
an SAE. 
 
Is life-threatening (patient is at immediate risk of death from the event as it 
occurred). 
 
Requires in-patient hospitalization (formal admission to a hospital for medical 
reasons) or prolongation of existing hospitalization. 
 
Results in persistent or significant disability/incapacity. 
 
Results in a congenital anomaly or birth defect. 
 
Important medical events that may not result in death, are not life-threatening, or do 
not require hospitalization may be considered SAEs when, based on appropriate 
medical judgment, they may jeopardize the patient and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
50 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home or the development of drug dependency or drug abuse. 
 
8.1.2.1 Events or Outcomes Not Qualifying as Serious Adverse Events 
 
The following are not considered SAEs and therefore do not need to be reported as 
 
such: 
 
Pre-planned or elective hospitalization including social and/or convenience 
situations (e.g. respite care). 
 
Hospital visits of less than 24 hours duration (e.g. patient presents to the emergency 
room, but is not admitted to a ward). 
 
Overdose of either BMS study drug or concomitant medication unless the event 
meets SAE criteria (e.g. hospitalization). However, the event should still be captured 
as a nonserious AE on the appropriate eCRF page. 
 
Events of progression of the patient’s underlying cancer as well as events clearly 
related to progression of the patient’s cancer (signs and symptoms of progression) 
should not be reported as a serious adverse event unless the outcome is fatal within 
the safety reporting period. If the event has a fatal outcome within the safety 
reporting period, then the event of Progression of Disease must be recorded as an 
AE and as a SAE with CTCAE Grade 5 (fatal outcome) indicated. 
8.1.3 
Progression of Malignancy 
Progression of a patient’s malignancy should not be considered an AE or SAE, unless 
in the Investigator’s opinion, study treatment resulted in an exacerbation of the 
patient’s condition. If disease progression results in death or hospitalization while 
on study or within 100 days of the last dose, progressive disease will be considered 
an SAE. 
8.1.4 
Life‐threatening Events 
A life-threatening event is any AE that places the patient at immediate risk of death 
from the reaction as it occurs. It is not a reaction that had it occurred in a more 
severe form, might have caused death. 
8.1.5 
Hospitalization or Prolongation of Hospitalization 
Hospitalization encompasses any inpatient admission (even for less than 24 hours) 
resulting from a precipitating, treatment-emergent adverse event. For chronic or 
long-term patients, inpatient admission also includes transfer within the hospital to 
an acute or intensive care inpatient unit. Hospitalizations for administrative reasons 
or a non-worsening preexisting condition should not be considered AEs (e.g. 
admission for workup of a persistent pretreatment laboratory abnormality, yearly 
physical exam, protocol-specified admission, elective surgery). Pre-planned 
treatments or surgical procedures should be noted in the baseline documentation. 
Hospitalization because of an unplanned event will be deemed an SAE. 
Prolongation of hospitalization is any extension of an inpatient hospitalization 
beyond the stay anticipated or required for the original reason for admission. 
8.1.6 
Significant Disability 
Disability is a substantial disruption of the patient’s ability to conduct normal life 
functions. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
51 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
8.1.7 
Pregnancy 
Male participants should refrain from fathering a child or donating sperm during the 
study and for 7 months following the last dose of nivolumab. 
Pregnancy of the patient’s partners is not considered to be an adverse event. 
However, the outcome of all pregnancies (spontaneous miscarriage, elective 
termination, ectopic pregnancy, normal birth or congenital abnormality) should, if 
possible, be followed up and documented.  
The outcome of any conception occurring from the date of the first dose until 7 
months after the last dose should be followed up and documented. 
All outcomes of pregnancy should be reported to BMS. 
8.1.8 
Medical Significance 
An event that is not fatal or life-threatening and that does not necessitate 
hospitalization may be considered serious if, in the opinion of the Investigator, it 
jeopardizes the patient’s status and might lead to medical or surgical intervention to 
prevent any of the outcomes described in section 7.1.2. Such medically significant 
events could include allergic bronchospasm requiring intensive treatment in the 
emergency room or at home, blood dyscrasias that do not result in inpatient 
hospitalization, or the development of drug dependency or abuse. 
 
8.1.9 
Deaths 
All deaths that occur during the study, or within the protocol-defined 100-day 
post-study follow-up period after the administration of the last dose of study 
treatment, must be reported as follows: 
 
Death that is clearly the result of disease progression should be reported to 
the study monitor at the next monitoring visit, be documented, and reported 
as an SAE. 
 
Where death is not due (or not clearly due) to progression of the disease 
under study, the AE causing the death must be reported to the study monitor 
as a SAE within 24 hours. The report should contain a comment regarding 
the co-involvement of progression of disease, if appropriate, and should 
assign main and contributory causes of death.   
 
Deaths with an unknown cause should be reported as a SAE., but followup 
should be done to determine the cause of death.  If a cause of death is 
determined, the event term of “death” must be updated at that time.    A post 
mortem maybe helpful in the assessment of the cause of death, and if 
performed a copy of the post-mortem results should be forwarded to BMS 
within the usual timeframes. 
 
The most recent version of the NCI CTCAE handbook will be used for adverse event 
descriptions and grading. 
 
All AEs (including SAEs and AESIs) occurring during the study are to be followed up in 
accordance with good medical practice until resolved; judged no longer clinically 
significant; or, if a chronic condition, until fully characterized through 100 days after the last 
dose of study drug. Any SAEs, AESIs, and treatment-related Grade 3/4 AEs must be followed 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
52 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
until resolution or stabilization, or until lost to follow-up. After the 100-day window, 
treatment-related SAEs and all AESIs, irrespective of causality, do not need to be reported.  
 
8.2 
Expectedness 
 
Adverse events can be considered, “expected,” or, “unexpected.” 
 
8.2.1  
Expected Adverse Events 
Expected adverse events are those that have been previously identified as resulting 
from administration of the agent. An adverse event can be considered expected 
when it appears in the same nature severity and specificity as what is in the current 
adverse event list of the Investigator’s Brochure. 
 
 
8.2.2 
Unexpected Adverse Events 
An adverse event can be considered unexpected when the nature, intensity or 
frequency of which is not consistent with the current adverse event list of the 
Investigator’s Brochure, contact the lead site, principal investigator or sponsor to 
confirm unexpected adverse events when necessary.   
8.3 
Recording and Grading 
8.3.1 
Recording 
All observed or volunteered adverse events, regardless of treatment group, severity, 
suspected causal relationship, expectedness, or seriousness will be documented. 
A clinically significant change in a physical examination finding or an abnormal test 
result (i.e., laboratory, X-ray, EKG) should be recorded as an AE, if it: 
 
Is associated with accompanying symptoms. 
 
Is suggestive of organ toxicity. 
 
Requires additional diagnostic testing or medical or surgical 
intervention. 
 
Leads to a change in study dosing or discontinuation from the study. 
 
Is considered clinically significant by the Investigator. 
 
An abnormal test result that is subsequently determined to be in error does not 
require recording as an adverse event, even if it originally met one or more of the 
above criteria. 
8.3.2 
Grading Severity 
All adverse events will be graded for intensity on a scale of 0 to 5. Severity grades 
will be recorded and based on the most recent version of the NCI CTCAE handbook. 
8.3.3 
Attributing Causality 
 
 
Medical judgment should be used to determine the cause of the AE considering  
 
 
all relevant factors such as, but not limited to, the underlying study indication,  
 
 
coexisting disease, concomitant medication, relevant history, pattern of the AE,  
 
 
temporal relationship to the study medication, dechallenge or rechallenge with  
 
 
the study drug (Table 3).  

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
53 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Not Related 
To Study 
Drug 
• 
An AE that is clearly due to extraneous causes (e.g. concurrent disease, 
concomitant medications, disease under study, etc.) 
• 
It does not follow a reasonable temporal sequence from administration of 
the study drug. 
• 
It does not follow a known pattern of response to study drug 
• 
It does not reappear or worsen when study drug is restarted. 
• 
An alternative explanation is likely, but not clearly identifiable. 
Related to 
Study Drug 
• 
An AE that is difficult to assign to alternative causes. 
• 
It follows a strong or reasonable temporal sequence from administration of 
study drug. 
• 
It could not be reasonably explained by the patient’s clinical state, 
concurrent disease, or other concomitant therapy administered to the 
patient.  
• 
It follows a known response pattern to study drug. 
• 
It is confirmed with a positive rechallenge or supporting laboratory data. 
Table 3. Relationship of Adverse Event to Study Drug 
8.4 
Reporting Adverse Events 
 
8.4.1 
Reporting Serious Adverse Events 
 
Following the subject’s written consent to participate in the study, all SAEs, whether 
 
related or not related to study drug, must be collected, including those thought to be 
 
associated with protocol-specified procedures. All SAEs must be collected that occur 
 
within 100 days of discontinuation of dosing.  
 
All SAEs must be collected that occur during the screening period. If applicable, 
SAEs must be collected that relate to any protocol-specified procedure (e.g. a follow-
up skin biopsy). The Investigator should report any SAE that occurs after these time 
periods that is believed to be related to study drug or protocol-specified procedure 
up to and including 100 days after the last dose received.  
 
 
All SAEs that occur following the subject’s written consent to participate in the 
 
study through 100 days of discontinuation of dosing must be reported to BMS 
 
Worldwide Safety, (Email: worldwide.safety@BMS.com; Fax: 1(609) 818-3804) 
 
whether related or not related to study drug. If applicable, SAEs must be 
 
collected that relate to any later protocol-specified procedure (e.g. a follow-up skin 
 
biopsy). 
 
 
An appropriate SAE form (e.g. ex-US = CIOMS form or USA = Medwatch form) 
 
should be used to report SAEs to BMS. The BMS protocol ID number must be 
 
included on whatever form is submitted by the Sponsor/Investigator.  
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
54 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
The CIOMS form is available at: http://www.cioms.ch/index.php/cioms-form-i  
 
The MedWatch form is available at: 
https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM0
48334.pdf  
 
 
 
SAEs, whether related or not related to study drug, and pregnancies must be 
 
reported to BMS within 24 hours. SAEs must be recorded on either CIOMS or 
 
MedWatch form & pregnancies must be reported on a Pregnancy Surveillance Form 
 
or can be submitted on the aforementioned SAE form to BMS. 
The Sponsor will reconcile the clinical database SAE cases (case level only) 
transmitted to BMS Global Pharmacovigilance (Worldwide.Safety@bms.com).  
Frequency of reconciliation should be every 3 months and prior to the database lock 
or final data summary. BMS Global Pharmacovigilance will email, upon request from 
the Investigator, the Global Pharmacovigilance reconciliation report. 
Requests for reconciliation should be sent to aepbusinessprocess@bms.com. The 
data elements listed on the Global Pharmacovigilance reconciliation report will be 
used for case identification purposes. If the Investigator determines a case was not 
transmitted to BMS Global Pharmacovigilance, the case should be sent immediately 
to BMS. 
 
 
IND application sponsors are required to notify FDA in a written safety report of: 
 
Any adverse experience associated with the use of the drug that is both serious 
and unexpected or, 
 
Any findings from tests in laboratory animals that suggest a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, and 
carcinogenicity.  
  
 
Adverse event means any untoward medical occurrence associated with the use of a 
 
drug in humans, whether or not considered drug related. 
 
 
Suspected adverse reaction means any adverse event for which there is a reasonable 
 
possibility that the drug caused the adverse event. For the purposes of IND safety 
 
reporting, “reasonable possibility” means there is evidence to suggest a causal 
 
relationship between the drug and the adverse event. A suspected adverse reaction 
 
implies a lesser degree of certainty about causality than an adverse reaction. 
 
Adverse reaction means any adverse event caused by a drug. Adverse reactions are 
 
a subset of all suspected adverse reactions where there is reason to conclude that 
 
the drug caused the event.   
 
Unexpected adverse event or suspected adverse reaction refers to an event or 
 
reaction that is not listed in the Investigator’s Brochure or is not listed at the 
 
specificity or severity that has been observed; or, if an Investigator’s Brochure is not 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
55 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
required or available, is not consistent with the risk information described in the 
 
general investigational plan or elsewhere in the current IND application. 
 
Serious adverse event or suspected adverse reaction refers to an event or reaction 
 
that, in the view of either the Investigator or Sponsor, results in any of the following 
 
outcomes: 
 
Death. 
 
A life-threatening adverse event. 
 
In-patient hospitalization or prolongation of existing hospitalization. 
 
A persistent or significant incapacity or substantial disruption of the    
ability to conduct normal life functions. 
 
A congenital anomaly or birth defect.  
 
A life-threatening adverse event or suspected adverse reaction is considered “life-
 
threatening” if, in the view of the investigator or sponsor, its occurrence places the 
 
patient or subject at immediate risk of death. It does not include an adverse event or 
 
suspected adverse reaction that, had it occurred in a more severe form, might have 
 
caused death. 
 
Important medical events that may not result in death, be life-threatening, or 
 
require hospitalization may be considered serious when, based upon appropriate 
 
medical judgment, they may jeopardize the patient or research subject and may 
 
require medical or surgical intervention to prevent one of the outcomes listed as 
 
serious.  
 
Mandatory Safety Reporting  
• Initial reporting: IND application sponsor must report any suspected adverse 
reaction or adverse reaction to study treatment that is both serious and unexpected.  
Unexpected serious suspected adverse reactions suggesting significant risk to 
human subjects must be reported to FDA as soon as possible but no later than 
within 15 calendar days following the sponsor’s initial receipt of the information. 
Unexpected fatal or life-threatening suspected adverse reactions represent 
especially important safety information and must be reported to FDA as soon as 
possible but no later than 7 calendar days following the sponsor’s initial receipt of 
the information. 
 
• Follow-up reporting: Any relevant additional information obtained by the sponsor 
that pertains to a previously submitted IND safety report must be submitted as a 
Follow-up IND Safety Report. Such report should be submitted without delay, as 
soon as the information is available but no later than 15 calendar days after the 
sponsor receives the information. 
 
All IND safety reports must be submitted on Form 3500A and be accompanied by 
Form 1571. The type of report (initial or follow-up) should be checked in the 
respective boxes on Forms 3500A and 1571.  
 
The submission must be identified as: 
•  “IND safety report” for 15-day reports or, 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
56 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
•  “7-day IND safety report” for unexpected fatal or life-threatening 
suspected adverse reaction reports or, 
•  “Follow-up IND safety report” for follow-up information. 
 
The report must be submitted to an appropriate Review division that has the 
responsibility to review the IND application under which the safety report is 
submitted. Each submission to this IND must be provided in triplicate (original plus 
two copies). Send all submissions to the following address: 
 
Food and Drug Administration 
Center for Drug Evaluation and Research 
Division of Oncology Products 1 
5901-B Ammendale Road 
Beltsville, MD 20705-1266 
8.4.2 
Reporting SAEs at Multi‐Site/Participating Institutions  
SAEs should be reported to the Lead site and BMS. 
9. 
CRITERIA FOR OUTCOME ASSESSMENT/THERAPEUTIC RESPONSE 
9.1 
Outcome Assessment 
All baseline evaluations will be performed as closely as possible to the beginning of 
treatment (within 7 days). For subsequent evaluations, the method of assessment and 
techniques will be the same as those used at baseline. 
Note: Any bone lesions, however, that are identified on the baseline CT or MRI 
studies and judged as providing meaningful information about nontarget disease 
status on the basis of their size or other features should be considered for inclusion 
in the follow-up assessments of nontarget lesions by the same imaging modality. 
 
Conventional CT, NM Bone Scan. 
CT Chest, Abdomen, Pelvis and NM Bone scans will be used to measure tumor 
response as a secondary endpoint per RECIST 1.1 Criteria. 
 
Tumor markers. 
       PSA measurements will be used to assess the primary endpoint. 
9.1.1 
Primary Endpoint 
The primary endpoint is defined as a PSA50 response, defined as a ≥ 50% decline in 
PSA from baseline, confirmed with a second measurement at least 4 weeks later. 
 
9.1.2 
Secondary Endpoints 
 
9.1.2.1  Safety 
This endpoint is defined as incidence of grade 3-5 toxicities based upon the 
most current CTCAE standard grading scales. 
 
 
 
9.1.2.2  PSA Progression‐Free Survival (PFS)  
PSA progression (PSA progression-free survival; PSA–PFS) will be defined 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
57 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
per PCWG3 guidelines. 
 
 
 
 
For those subjects showing an initial decline in PSA from baseline, is   
 
 
 
defined as an increase in PSA that is ≥ 25% and ≥ 2 ng/mL above the nadir,  
 
 
 
and which is confirmed by a second value ≥ 3 weeks later (i.e. a  
 
 
 
 
confirmed rising trend). 
 
 
 
 
For those subjects with no decline in PSA from baseline, is defined as an  
 
 
 
increase in PSA that is ≥ 25% and ≥ 2 ng/mL after 12 weeks. 
 
 
 
9.1.2.3  Progression–free Survival 
Time to radiographic or clinical progression or death, whichever comes first.  
 
Based on RECIST version 1.1 and PCWG3 definitions including:  
 
Progression of soft tissue lesions according to RECIST 1.1 Criteria.  
 
Progression of bone lesions detected with bone scan according to 
PCWG3 criteria.  
 
Radiologically-confirmed spinal cord compression or pathological 
fracture due to malignant progression, or other clinical event 
deemed to be cancer-related. 
 
 
 
9.1.2.4   Objective Response Rate 
Defined as the proportion of patients achieving a complete/partial response 
in target lesions (RECIST 1.1 Criteria). 
 
  
 
9.1.2.5    Durable Progression‐free Survival (durable‐PFS)  
Durable PFS will be defined as the proportion of patients without clinical or 
radiographic progression, as defined by PCWG3 criteria, or death at 24 
weeks from the start of treatment. 
 
  
 
9.1.2.6  Overall Survival (OS) 
Overall survival will be defined as the time from study enrollment to death 
or up to 2 years after last dose. 
This will be summarized using a Kaplan-Meier curve. 
 
9.2 
Therapeutic Response 
Response and progression will be evaluated in this study using a combination of the 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors 
(RECIST) Committee(42) and the guidelines for prostate cancer endpoints developed by the 
Prostate Cancer Clinical Trials Working Group (PCWG3).(43)
Patients will need to be re-evaluated for response every cycle according to the guidelines 
below.
9.2.1 
PSA 
Perform PSA testing at a minimum of 1-week intervals with the threshold PSA level 
at 2.0 ng/mL. To report PSA-based outcomes, PCWG3 recommends that the percent 
of change in PSA from baseline to 12 weeks (or earlier for those who discontinue 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
58 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
therapy) and the maximum decline in PSA that occurs at any point after treatment 
be reported for each patient using a waterfall plot. PSA measurements obtained 
during the first 12 weeks should not be used as the sole criterion for clinical 
decision making. 
9.2.2 
Measurable Disease 
According to RECIST 1.1, measurable disease is defined as at least 1 lesion > 10mm 
in its longest diameter as measured with conventional techniques (i.e. CT with slice 
cut of 5 mm, MRI). All tumor measurements will be taken using a ruler or calipers 
and recorded in millimeters (or decimal fractions of centimeters).  To be considered 
pathologically enlarged and measurable, a lymph node must be > 15 mm in short 
axis when assessed by CT scan (CT scan slice thickness recommended to be no 
greater than 5 mm).  
9.2.3 
Nonmeasurable Disease 
Following RECIST 1.1, all other lesions (or sites of disease) will be considered 
nonmeasurable disease. This includes small lesions (longest diameter < 10 mm 
using spiral CT scan), lymph nodes (shortest diameter > 10 mm to < 15 mm) and 
any of the following: 
 
Bone lesions. 
 
Ascites. 
 
Pleural or pericardial effusion. 
 
Lymphangitis cutis or pulmonis. 
 
Abdominal masses that are not confirmed and followed by imaging 
techniques. 
 
Cystic lesions. 
 
Lesions occurring within a previously irradiated area unless they are 
documented as new lesions since the completion of radiation therapy. 
 
Note. If only a single, asymptomatic bone lesion is present at baseline, and 
will be irradiated, the metastatic nature of this lesion must be 
confirmed by X-ray, CT, or MRI. 
9.2.4 
Target (nodal and visceral) Lesions 
Following RECIST 1.1 Criteria, progression in a nodal or visceral site (i.e. liver and 
lung) is sufficient to document disease progression. The presence or absence of 
nodal and visceral disease before and after treatment should be recorded 
separately. 
All measurable lesions (up to a maximum of 2 lesions per organ and 5 lesions in 
total) will be identified as target lesions to be measured and recorded at baseline. 
The target lesions should be representative of all involved organs. Target lesions 
will be selected on the basis of size (i.e. the largest area) and suitability for accurate, 
repeated measurements (either by imaging techniques or clinically). The sum of the 
longest diameter (LD) of all non-nodal and shortest diameter (nodal) target lesions 
will be calculated and reported as the baseline sum LD. The baseline sum LD will be 
used as a reference by which to characterize the objective tumor response. 
Because small lymph nodes are difficult to measure accurately and may not be 
malignant, to be considered pathologically enlarged and measurable, a lymph node 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
59 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
must be > 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). 
  
9.2.5 
Bone Lesions 
When the bone scan is the sole indicator of progression, disease progression in bone 
is defined as ≥ 2 new lesions seen on bone scan compared with a prior scan for used 
trial entry. In situations where scan findings suggest a flare reaction or where new 
lesion(s) may represent trauma, confirm these results with other imaging 
modalities (e.g. MRI or fine-cut CT). If many new areas of uptake are observed, 
confirmation is generally not necessary. 
9.2.6 
Nontarget Lesions 
All other lesions (or sites of disease) will be identified as nontarget lesions and 
recorded at baseline. Nontarget lesions will include measurable lesions that exceed 
the maximum number per organ (2) or total of all involved organs (5), as well as 
nonmeasurable lesions. The presence or absence of these lesions will be recorded 
on the CRF and should be evaluated at the same assessment time points as all target 
lesions. 
9.2.7 
New Lesions 
 
The appearance of new malignant lesions denotes disease progression. There are 
 
no specific criteria for the identification of new radiographic lesions; however, the 
 
finding of a new lesion should be unequivocal, i.e. not attributable to differences in 
 
scanning technique, change in imaging modality or findings thought to represent 
 
something other than tumor (for example, some “new” bone lesions may be simply 
 
healing or flare of pre-existing lesions).  
 
9.3 
Response Criteria for Primary and Secondary Endpoints 
9.3.1 
Measurable Soft‐tissue Lesions 
When evaluating soft-tissue lesions, the definitions in Table 4 apply. 
Table 4. RECIST 1.1 Response Criteria for Target Lesions 
Response 
Evaluation of Target Lesions 
Complete response 
(CR) 
Disappearance of all target lesions. Any pathological lymph 
nodes (whether target or non-target) must have reduction in 
short axis to < 10 mm.  
Partial response (PR) 
At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.  
Progressive disease 
(PD)  
At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this 
includes the baseline sum if that is the smallest on study). In 
addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of ≥ 5 mm. (Note: the 
appearance of one or more new lesions is also considered 
progression). 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
60 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Stable disease (SD) 
Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest 
sum diameters while on study.  
 
In some circumstances, it may be difficult to distinguish residual disease from 
normal tissue. When the evaluation of complete response depends on this 
determination, it is recommended that the residual lesion be investigated (e.g. fine 
needle aspirate or biopsy) before confirming the complete response status. 
Changes in nodal and visceral sites should be recorded and reported separately, and 
lymph nodes in the pelvis must measure ≥ 15 mm in shortest diameter to be 
considered target lesions. Complete elimination of disease at a particular site 
should be recorded separately. Any favorable change should be confirmed using a 
second follow-up scan. 
9.3.2 
PSA 
For each patient, use a waterfall plot to report the percent change in PSA from 
baseline to 12 weeks (or earlier for those who discontinue therapy) and the 
maximum decline in PSA that occurs at any point after treatment.  We will also 
report the proportion of patients to achieve a 50% of greater decrease in PSA from 
baseline (i.e. PSA50 response rate). 
9.3.3 
Bone 
Record post-treatment changes as either “no new lesions” or “new lesions.” 
 
In the absence of clearly worsening soft-tissue (nodal and visceral) disease or 
disease-related symptoms, progression at the first scheduled assessment should be 
confirmed on a second scan performed ≥ 6 weeks later. In the rare case where 
visible lesions disappear, this too should be confirmed. 
9.3.4 
Nontarget Lesions 
When assessing nontarget lesions, the definitions in Table 5 will apply. 
 
Table 5. RECIST 1.1 Response Criteria for Nontarget Lesions 
Response 
Evaluation of Nontarget Lesions 
Complete response 
(CR) 
The disappearance of all nontarget lesions and 
normalization of tumor marker levels. All lymph nodes must 
be non-pathological in size (< 10 mm short axis). 
Non-CR/non-PD 
The persistence of one or more nontarget lesions and/or 
maintenance of tumor marker levels above the normal 
limits. 
Progressive disease 
(PD) 
The appearance of one or more new lesions and/or 
unequivocal progression of existing nontarget lesions. 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
61 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
9.4 
Criteria for Progressive Disease. 
9.4.1 
Measurable Soft‐tissue Lesions 
When evaluating soft-tissue lesions, the definitions in Table 4 apply. 
In some circumstances, it may be difficult to distinguish residual disease from 
normal tissue. When the evaluation of complete response depends on this 
determination, it is recommended that the residual lesion be investigated (e.g. fine 
needle aspirate or biopsy) before confirming the complete response status. 
Progression in a nodal or visceral site should be defined using RECIST 1.1 Criteria 
(Table 4).  
9.4.2 
PSA 
Per the PCWG3, PSA progression is defined as the date that a 25% or greater 
increase and an absolute increase of 2 ng/mL or more from the nadir is documented 
and confirmed by a second value obtained 3 or more weeks later. Where no decline 
from baseline is documented, PSA progression is defined as a 25% increase from the 
baseline value along with an increase in absolute value of 2 ng/mL or more after 12 
weeks of treatment. 
9.4.3 
Bone 
Progressing disease on bone scan is considered when at least 2 new lesions are 
observed. Yet, progression remains unconfirmed unless at least 2 additional new 
lesions appear at a subsequent time point. 
Unless clinically indicated, there is no need to perform a follow-up bone scan before 
12 weeks of treatment. To define disease progression requires a confirmatory scan 
(which shows additional new lesions compared with the first follow-up scan) 
performed ≥ 6 weeks later. When further progression is documented on the 
confirmatory scan, the date of progression recorded for the trial is the date of the 
first scan that shows the change. 
9.4.4 
Nontarget Lesions 
When assessing nontarget lesions, the definitions in Table 5 apply.
 
10. 
DATA REPORTING AND REGULATORY REQUIREMENTS 
 
 
Multicenter Guidelines 
 
The Protocol Chair 
 
The Protocol Chair, Dr. Mark Markowski is responsible for performing the following tasks: 
 
Coordinating, developing, submitting, and obtaining approval for the protocol as 
well as its subsequent amendments. 
 
Assuring that all participating institutions are using the correct version of the 
protocol. 
 
Taking responsibility for the overall conduct of the study at all participating 
institutions and for monitoring the progress of the study. 
 
Reviewing and ensuring reporting of Serious Adverse Events (SAEs). 
 
Reviewing data from all sites. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
62 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Lead Center 
The Lead Center (Johns Hopkins University) is responsible for performing the following 
tasks: 
 
Ensuring that IRB approval has been obtained at each participating site prior to the 
first patient registration at that site, and maintaining copies of IRB approvals from 
each site. 
 
Managing central patient registration. 
 
Collecting and compiling data from each site. 
 
Establishing procedures for documentation, reporting and submitting of AEs and 
SAEs to the Protocol Chair and all other applicable parties. 
 
Facilitating audits by securing selected source documents and research records 
from participating sites for audit, or by auditing at participating sites. 
 
Participating PCCTC Sites 
Participating sites are responsible for performing the following tasks: 
 
Following the protocol as written, and the guidelines of Good Clinical Practice (GCP). 
 
Submitting data to the Lead Center.  
 
Registering all patients with the Lead Center by submitting patient registration form 
and signed informed consent promptly. 
 
Providing sufficient experienced clinical and administrative staff and adequate 
facilities and equipment to conduct a collaborative trial according to the protocol. 
 
Maintaining regulatory binders on site and providing copies of all required 
documents to the Lead Center. 
 
Collecting and submitting data according to the schedule specified by the protocol. 
 
10.1 
Data Entry 
Data collected during this study will be entered into a secure database. Staff at Johns 
Hopkins University will be responsible for the initial study configuration and setup in the 
CRMS database and for any future changes. 
10.1.1 Case Report Forms Completion 
Electronic Case report forms will be generated by the coordinating center for the 
collection of all study data. Investigators will be responsible for ensuring that the 
CRFs are kept up-to-date. 
The paper Eligibility Checklist CRF must be completed using black ink.  Any errors 
must be crossed out so that the original entry is still visible, the correction clearly 
indicated and then initialed and dated by the individual making the correction. 
eCRFs will be completed within 2 weeks of the patient coming to the clinic and all 
relevant supporting documentation such as scans, progress notes, nursing notes, 
blood work, pathology reports, etc., will be submitted via email to the SKCCC 
Coordinating Center Study Manager.  All patient names or other identifying 
information will be removed prior to being sent to the Coordinating Center (SKCCC) 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
63 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
or non-redacted source documents can be sent via a password-protected/secured 
document transfer based on each institution’s guidelines.  
Authorized representatives of the Coordinating Center (SKCCC) may visit the 
satellite sites to perform audits or inspections, including source data verification. 
The purpose of these audits or inspections is to systematically and independently 
examine all trial-related activities and documents to determine whether these 
activities were conducted and data were recorded, analyzed, and accurately 
reported according to the protocol, Good Clinical Practice (GCP), and any applicable 
regulatory requirements. 
10.1.2 Source Documents 
Study personnel will record clinical data in each patient’s source documents (i.e. the 
patient’s medical record). Source documentation will be made available to support 
the patient research record. Study monitors will review entries on the CRFs at 
regular intervals, comparing the content with source documents. 
10.1.3 Record Retention 
The Investigator will maintain adequate and accurate records to enable the conduct 
of the study to be fully documented and the study data to be subsequently verified. 
After study closure, the Investigator will maintain all source documents, study-
related documents, and the CRFs. Because the length of time required for retaining 
records depends upon a number of regulatory and legal factors, documents should 
be stored until the Investigator is notified that the documents may be destroyed. In 
this study, records are to be retained and securely stored for a minimum of 5 years 
after the completion of all study activities. 
10.2 
Data Management 
10.2.1 Lead Research Program Coordinators 
A Lead research program coordinator at the coordinating center will be assigned to 
the study. A Lead Research Program Coordinator will manage the study activities at 
each of the participating sites. The responsibilities of the Lead Research Program 
Coordinator include project compliance, data collection, data entry, data reporting, 
regulatory monitoring, problem resolution and prioritization, and coordination of 
the activities of the protocol team. 
10.3 
Study Monitoring and Quality Assurance 
Regularly scheduled registration reports will be generated to monitor patient accruals and 
the completeness of registration data. Routine data quality reports will be generated to 
assess missing data and inconsistencies. Accrual rates and the extent and accuracy of 
evaluations and follow-up will be monitored periodically throughout the study period, and 
potential problems will be brought to the attention of the principal investigator for 
discussion and action. 
Random-sample data quality and protocol compliance audits will be conducted by the study 
team at least once a year, more frequently if indicated. Audits by the coordinating center 
may entail (1) shipping source documents and research records for selected patients from 
participating sites to the coordinating center for audit, or (2) on-site auditing of selected 
patient records at participating sites. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
64 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
All clinical work conducted under this protocol is subject to Good Clinical Practice (GCP) 
guidelines. This includes inspection of study-related records by the lead site, sponsor, its 
designee, or health authority representatives at any time. 
 
Data and Safety Monitoring:  
This is a DSMP Medium Risk study under the SKCCC Data and Safety Monitoring Plan 
(6/5/2020). Data Monitoring of this protocol will occur annually. The protocol will be 
monitored internally at SKCCC by the Principal Investigator. The SKCCC Compliance 
Monitoring Program will provide external monitoring for JHU affiliated sites in accordance 
with SKCCC DSMP (Version 6.0, 02/21/2019). The SMC Subcommittee will determine the 
level of patient safety risk and level/frequency of monitoring.  
Additionally, scheduled meetings will take place monthly and will include the protocol 
Principal Investigator, research nurse, data manager, and, when appropriate, the 
collaborators, subinvestigators, and biostatistician involved with the conduct of the 
protocol. 
During these meetings the investigators will discuss matters related to: the safety of 
protocol participants, validity and integrity of the data, enrollment rate relative to 
expectation, characteristics of participants, retention of participants, adherence to protocol 
(potential or real protocol violations), data completeness, and progress of data for 
secondary objectives. 
 
10.4 
Clinical Trial Agreement 
This trial is being conducted under one or more clinical trial agreements that contain, 
among other terms, the publication policy, indemnity agreements, and financial 
arrangements for the study.
11. 
STATISTICAL CONSIDERATIONS 
The primary endpoint will be the proportion of subjects who achieve a PSA response, 
defined as a 50% or greater decline in PSA from baseline, confirmed on a subsequent 
measurement at least 4 weeks apart. The treatment regimen would be considered of 
insufficient activity for further study in this population if the PSA response rate is 25% or 
less. The sample size is calculated to detect an improved PSA response rate from 25% (null 
hypothesis) to 45% (alternative). A minimax Simon two stage design is planned. A total of 
23 patients will be entered in the first stage. A planned analysis will be performed 12 weeks 
after the last patient in the first stage receives the first dose of nivolumab.  If ≤ 5 subjects 
have a PSA response, the study will be terminated and we will conclude the regimen is 
ineffective. If ≥ 6 subjects respond, then an additional 16 patients will be studied, for a total 
of 39 patients. If a total of ≤ 13 subjects respond in stage one and two combined, we 
consider this regimen ineffective. If a total of ≥ 14 respond, we conclude the regimen is 
promising and warrants further study. The maximum sample size will be increased to 44 
patients to account for 10% possible dropouts and unevaluable patients.   
 
This design provides 90% power to detect an absolute 20% increase in PSA response rate 
with a one-sided type I error of 0.1. The probability of early stopping is 0.49 under the null 
hypothesis that the PSA50 response rate is 25%.  
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
65 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
11.1 
Study Endpoints 
 
11.1.1 Analysis of the Primary Endpoint 
The primary endpoint of this study is PSA50 response, defined as a decrease in the 
PSA to 50% less than the baseline PSA upon enrollment in the trial. The decrease 
must be confirmed by a second measurement at least 4 weeks apart. For purposes of 
meeting the primary endpoint, patients will be considered to have done so if they 
have a PSA50 response only while on therapy with Testosterone +/- Nivolumab. PSA 
values will be measured each cycle during the trial.  All patients who are 
administered at least one dose of Testosterone will be considered evaluable for the 
primary endpoint. If patients do not have follow-up PSAs after initiation of 
Testosterone therapy due to withdrawing consent or being lost to follow-up for 
example, then they will be replaced.   
We will estimate the PSA50 response rate, along with the exact 95% confidence 
interval, for the population of patients. 
   
11.1.2 Analysis of Secondary Endpoints 
 
11.1.2.1 Safety 
Patients will be assessed for toxicities at each clinical evaluation. Toxicities 
will graded according to the most current CTCAE standardized grading 
scales.  The incidence of grade 3-5 toxicities will be reported. Patients will be 
assessed for toxicity as long as they are taking Testosterone +/- Nivolumab, 
and patients will continue to be followed if treatment is discontinued for 
toxicity until the toxicities improve to grade 1 or resolve. 
Toxicities will be reported as a tabulated table by type and grade. 
 
 
11.1.2.2 PSA Progression‐free Survival (PSA‐PFS)  
A standard definition of PSA progression per PCWG3 will be used. PSA-PFS 
will be defined as an increase in 25% over a nadir value, confirmed by a 
follow-up PSA at least 4 weeks apart. If patients are removed from study 
prior to PSA progression, then they will be censored at that time. 
 
 
We will use the Kaplan-Meier method to summarize the median PSA PFS. 
 
   
11.1.2.3 Progression‐free Survival (PFS) 
Progression-free survival will be measured from the time of first dose to 
objective tumor progression as defined by RECIST 1.1 for progressive 
disease or death and summarized using a Kaplan-Meier curve. Progression 
will be assigned to the earliest observed time. Patients whose disease has 
not progressed at follow-up will be censored at the date when the last tumor 
assessment determined a lack of progression.  
 
 
We will use the Kaplan-Meier method to summarize the median PFS. 
 
 
11.1.2.4 Objective Response Rate (ORR) 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
66 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
The objective response rate is defined as the percentage of patients who 
achieve an objective response by RECIST 1.1 criteria (i.e. Complete response 
or Partial Response) to Testosterone +/- Nivolumab. 
We will estimate the objective response rate, along with the exact 95% 
confidence interval, for the population of patients with RECIST 1.1 evaluable 
disease. 
 
 
 
11.1.2.5 Durable Progression‐free Survival 
 
 
 
Durable PFS will be defined as the proportion of patients without clinical or  
 
 
 
radiographic progression or death at 24 weeks from start of treatment. 
 
 
 
11.1.2.6 Overall Survival (OS) 
Overall survival will be defined as the time from study enrollment to death 
or up to 2 years after the last dose of study treatment.  
This will be analyzed as a Kaplan-Meier plot. 
 
11.1.3 Analysis of Exploratory Endpoints 
 
 
11.1.3.1 Estimate the Percentage of Patients with a Pathogenic Somatic or Germline  
 
 
 Mutation in a HR or MMR Gene Mutation 
The somatic DNA mutations present in the tumor will be identified through 
Foundation Medicine sequencing. Germline DNA mutation testing per 
standard of care practice will be done using clinical-grade testing in a CLIA-
certified laboratory (i.e. COLOR genomics) for consenting subjects only. 
Patients with a germline or somatic deleterious mutation or deletion in the 
pre-specified gene list (BRCA1, BRCA2, ATM, CHEK2, NBN, RAD50, RAD51C, 
RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, 
FANCG, FANCI, FANCL, FANCM, MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 
and PMS2) will be considered biomarker positive. For biomarker positive 
and biomarker negative subjects, we will calculate PSA50 response rates with 
confidence intervals for hypothesis generation.  
   
 
11.1.3.2 PD‐1, PD‐L1, CD4, CD8, FOXP3, γH2AX, RAD51, 53BP1 Protein Levels:  
Subjects will have pre-treatment, on-treatment (and at progression) tumor 
biopsy specimens analyzed.  IHC staining for PD-1 and PD-L1 will be 
performed on the pre-treatment samples and scored as <1%, 1-5%, 5-10%, 
>10% and the results will be associated with responses for both proteins, 
separately, using descriptive statistics and Fisher’s Exact Tests. 
Immunofluorescence will be used to quantify the median intensity of each 
gamma-H2AX, RAD51m and 53BP1 foci per cell as well determine the 
median number of foci per cell on the pretreatment biopsies. Using   
 analytical microscopy, Drs. Meeker and Heaphy have developed imaging 
software which can isolate single nuclei and quantify both the intensity and 
number of immunofluorescent foci per nucleus (i.e. per cell). Using FFPE 
tissue obtained at biopsy, we will examine the change in DNA damage foci 
number and intensity (reported as median percent change) induced by BAT 
+/- Nivolumab in PSA50 responders versus non-responders using a T-test. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
67 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Using imaging software, we will count the number of CD4+ and CD8+ 
lymphocytes in pre-treatment and on-treatment biopsies. We will correlate 
PSA50 responses with CD4+ and CD8+ lymphocyte tumor infiltration. 
 
 
11.1.3.3 MANAs/TAAs Assay  
Whole-exome sequencing will be performed on pre-treatment samples, after 
12 weeks of BAT lead-in therapy, and post-progression tumor and matched 
normal samples. Exome data will be applied in a neoantigen prediction 
pipeline that evaluates antigen processing, MHC binding, and gene 
expression to generate neoantigens specific to the patient’s HLA haplotype. 
Truncal neoantigens will be identified by correcting for tumor purity and 
ploidy. Putative neoantigens will then be used to generate peptides and 
stimulate autologous T cells, followed by TCR next-generation sequencing. 
 
 
11.1.3.4  Cytokines and Chemokines Analysis 
Milliplex human cytokine/chemokine Immunology Multiplex Assay 
(Millipore-Sigma) will be used to assay acute effects of BAT on production of 
cytokines and chemokines. Plasma samples are obtained at prior to the first 
BAT injection on C1D1, 3 hours after the first BAT injection (C1D1), 3 days 
after the first BAT injection (C1D4), prior to C2D1, and prior to C7D1.  
Samples will be processed and stored in the Denmeade Laboratory and 
analyzed by the Immune Processing Core Lab at Johns Hopkins. 
11.2 
Analysis Populations 
11.2.1 Intent‐to‐treat/Response‐to‐treatment/Evaluable Population 
All patients who meet eligibility criteria and receive at least 1 dose of testosterone 
will be included in the main analysis of the response rate, even if there are major 
protocol deviations (e.g. incorrect treatment schedule or drug administration). Each 
patient will be assigned to one of the following categories: 
 
Table 6. Categories for Response to Treatment 
Category 
Response 
1 
Complete response 
2 
Partial response 
3 
Stable disease 
4 
Progressive disease 
5 
Early death from malignant disease 
6 
Early death from toxicity 
7 
Early death from other causes 
8 
Unknown (not assessable/insufficient data) 
NOTE:  By arbitrary convention, category 8 designates unknown status in a 
clinical database. Patients in response categories 4 to 6 will be 
considered to have treatment failure (disease progression) Patients in 
response categories 7 and 8 will be censored (i.e. stable disease) or 
considered disease progression at the discretion of the PI. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
68 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
Conclusions are to be based on the population of all eligible patients. Subanalyses 
may be performed on various subsets of patients, such as those with no major 
protocol deviations or those who continued in the study for the entire treatment 
period (i.e. did not withdraw prematurely). Subanalysis will not serve as the basis 
for drawing conclusions concerning treatment efficacy. 
11.2.2 Safety Population 
All patients enrolled in the study will be included in the safety analysis population 
and considered evaluable for toxicity and safety from the time of their first dose. 
Demographic and baseline characteristics for the safety population will be 
summarized by number and percent for categorical data (e.g. sex, race/ethnicity) 
and by descriptive statistics for continuous data (e.g. weight, vital signs, EKG 
readings, disease status). 
11.3 
Safety Analysis 
11.3.1 Evaluation of Adverse Events 
Treatment-emergent adverse events will be translated from investigator terms to 
MedDRA v.20.1 terminology and summarized (number and percentage of patients) 
for all patients who receive at least 1 dose. Adverse event summaries will be 
organized by body system, frequency of occurrence, intensity (i.e. severity grade), 
and causality or attribution. Patients who experience an adverse event more than 
once will be counted only once. The occurrence with the maximum severity will be 
used to calculate intensity. 
11.3.2 Evaluation of Serious Adverse Events and Premature Withdrawals 
Adverse events deemed serious and those resulting in treatment withdrawal or 
death will be summarized separately. Narrative paragraphs will be generated to 
describe the circumstances surrounding each SAE and death. 
11.3.3 Evaluation of Laboratory Parameters and Assays 
Selected clinical laboratory parameters will be summarized and clinically significant 
changes from baseline will be discussed. 
11.3.4 Extent of Exposure 
Treatment exposure will be summarized for all patients, including dose 
administration, number of cycles, dose modifications or delays, and duration of 
therapy. 
12. 
PROTECTION OF HUMAN SUBJECTS 
12.1 
 
Ethical Considerations 
This study will be conducted in compliance with the protocol, GCP guidelines 
established by the International Conference on Harmonization, and the ethical 
standards set forth in the Declaration of Helsinki 2004 (available at: 
www.laakariliitto.fi/e/ethics/helsinki.html). 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
69 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
12.2 
 
Protocol Amendments 
Before starting the study, the protocol must be approved by each institution’s IRB or 
Independent Ethics Committee (IEC). Amendments to the protocol may be made 
only with consent of the lead site/sponsor and principal investigator and are subject 
to IRB approval before instituting. 
12.3 
 
Written Informed Consent 
Before obtaining consent, members of the study team will review the rationale for 
the treatment program with the patient. The discussion will review the alternatives 
available (including hormonal therapy, chemotherapy, or supportive care as 
appropriate), the potential benefits of this program, the risks and the probability of 
their occurrence, and the procedures to minimize these risks. Should an adverse 
event occur, the provisions available to ensure medical intervention will also be 
reviewed. Why the risks are reasonable in relation to the anticipated benefits, 
incentives, or costs that will or may be incurred as a result of participating in the 
study, as well as the efforts to maintain confidentiality, will also be discussed with 
the patient. 
Patients will be required to sign and date (in duplicate) a statement of informed 
consent that meets the requirements of the Code of Federal Regulations (Federal 
Register Vol. 46, No. 17, January 27, 1981, part 50) and the IRB. The medical record 
will include a statement that written informed consent was obtained (and document 
the date that it was obtained) before the patient is enrolled in the study. The original 
signed document will become part of the patient’s medical record, a copy will be 
forwarded to the lead site/sponsor pursuant to sponsor registration, and a copy will 
be sent home with each patient. 
The consent form will include the following: 
 
The nature and objectives, potential toxicities, and benefits of the intended 
study. 
 
The length of therapy and likely follow-up required. 
 
Alternatives to the proposed therapy (including available standard and 
investigational therapies). 
 
The name of the investigator(s) responsible for the protocol. 
 
The right of the patient to accept or refuse treatment and to withdraw from 
participation in this study. 
 
Text regarding the coordinating center should be added to all institutional 
informed consent documents. 
12.4 
 
Protection of Privacy 
Patients will be informed of the extent to which their confidential health 
information generated from this study may be used for research purposes. After this 
discussion, they will be asked to sign a Notice of Privacy Practice research 
authorization/HIPAA form. The original signed documents will become part of the 
patient’s medical records, and each patient will receive a copy of the signed 
documents. The use and disclosure of protected health information will be limited to 
the individuals described in the research authorization form. The research 
authorization form must be completed by the principal investigator and approved 
by the IRB. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
70 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
12.5 
 
Terminating or Modifying the Study 
Adverse event and laboratory data from this trial will be assessed by the medical 
monitor (Dr. Mark Markowski) on an ongoing basis. At least quarterly, data from the 
clinical database will be reviewed. The results of this review will be shared with all 
investigators either in writing or as part of a teleconference. SAEs will be reviewed 
as they are reported to the lead site/sponsor, and the medical monitor will make an 
assessment regarding the safety of continuing or modifying the study. This 
assessment will be shared with the investigators either in writing or as part of a 
teleconference as well as with BMS. Should the assessment of either the lead 
site/sponsor or the principal investigator be that the study should be terminated, 
the study will be closed to further accrual. Patients who are receiving Testosterone 
+/- Nivolumab will be assessed individually by the investigator to see if it is in the 
patients’ best interest to continue, which might be the case for a patient that is 
responding to the intervention. Follow-up safety assessments will be performed for 
all patients who are terminated from the study prematurely. Any planned data 
disclosures will also be discussed with BMS.

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
71 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
13. 
REFERENCES 
 
1. 
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians 
2016;66(1):7-30. 
2. 
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, 
Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly 
WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small 
EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff 
PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: 
Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin 
Oncol 2016;34(12):1402-1418. 
3. 
Langeler EG, van Uffelen CJ, Blankenstein MA, van Steenbrugge GJ, Mulder E. Effect of 
culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. 
The Prostate 1993;23(3):213-223. 
4. 
Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen 
deprivation: hormone-independent growth, repression of proliferation by androgen, and 
role for p27Kip1 in androgen-induced cell cycle arrest. Molecular endocrinology 
1998;12(7):941-953. 
5. 
Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. 
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for 
bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. The Prostate 
2012;72(14):1491-1505. 
6. 
Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. 
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate 
cancer cells. Proceedings of the National Academy of Sciences of the United States of 
America 2006;103(41):15085-15090. 
7. 
Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits 
prostate cancer proliferation. Cell cycle 2007;6(6):647-651. 
8. 
Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, 
Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the 
ligand-dependent full-length androgen receptor and its splice variants in castration-
resistant prostate cancer. Cancer research 2012;72(14):3457-3462. 
9. 
Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A. Testosterone boosts for treatment of 
castration resistant prostate cancer: an experimental implementation of intermittent 
androgen deprivation. The Prostate 2013;73(15):1699-1709. 
10. 
Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, 
Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-
induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. 
Nature genetics 2010;42(8):668-675. 
11. 
Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, Berney DM, Lu YJ. 
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer 
research 2010;70(23):9544-9548. 
12. 
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, 
Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: 
a potential mechanism of immune evasion. Nature medicine 2002;8(8):793-800. 
13. 
Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, Weller M, 
Wiendl H. Expression of the B7-related molecule B7-H1 by glioma cells: a potential 
mechanism of immune paralysis. Cancer research 2003;63(21):7462-7467. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
72 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
14. 
Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. Journal of 
molecular medicine 2003;81(5):281-287. 
15. 
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature 
reviews Cancer 2012;12(4):252-264. 
16. 
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, 
Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory 
B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential 
therapeutic target. Proceedings of the National Academy of Sciences of the United States of 
America 2004;101(49):17174-17179. 
17. 
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, 
Blute ML, Leibovich BC, Kwon ED. Costimulatory molecule B7-H1 in primary and metastatic 
clear cell renal cell carcinoma. Cancer 2005;104(10):2084-2091. 
18. 
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, 
Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated 
with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer 
research 2006;66(7):3381-3385. 
19. 
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, 
Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y. Clinical significance of 
programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human 
esophageal cancer. Clinical cancer research : an official journal of the American Association 
for Cancer Research 2005;11(8):2947-2953. 
20. 
Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of 
programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta 
histochemica 2006;108(1):19-24. 
21. 
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita 
H, Azuma M, Nakajima Y. Clinical significance and therapeutic potential of the programmed 
death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research 
2007;13(7):2151-2157. 
22. 
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection 
and immunosubversion. Nature reviews Immunology 2006;6(10):715-727. 
23. 
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, 
Topalian SL, Chen L. Colocalization of inflammatory response with B7-h1 expression in 
human melanocytic lesions supports an adaptive resistance mechanism of immune escape. 
Science translational medicine 2012;4(127):127ra137. 
24. 
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly 
immunogenic tumor cells by enhanced recruitment of effector T cells. International 
immunology 2005;17(2):133-144. 
25. 
Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, 
Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates 
cancer therapeutic immunity. Cancer research 2005;65(3):1089-1096. 
26. 
Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K. Anti-programmed death-1 
synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell 
immunotherapy providing therapeutic benefit to mice with established tumors. Clinical 
cancer research : an official journal of the American Association for Cancer Research 
2009;15(5):1623-1634. 
27. 
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade 
expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
73 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
melanoma tumors. Proceedings of the National Academy of Sciences of the United States of 
America 2010;107(9):4275-4280. 
28. 
Brendler H CW, Scott WW. Prostatic Cancer: Further investigation of hormone relationships. 
Arch Surg 1949:433-440. 
29. 
Prout GR, Jr., Brewer WR. Response of men with advanced prostatic carcinoma to 
exogenous administration of testosterone. Cancer 1967;20(11):1871-1878. 
30. 
Donati RM, Ellis H, Gallagher NI. Testosterone potentiated 32P therapy in prostatic 
carcinoma. Cancer 1966;19(8):1088-1090. 
31. 
Johnson DE, Haynie TP. Phosphorus-32 for intractable pain in carcinoma of prostate. 
Analysis of androgen priming, parathormone rebound, and combination therapy. Urology 
1977;9(2):137-139. 
32. 
Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, 
White-Hershey D, Gordon R, et al. Androgen priming and chemotherapy in advanced 
prostate cancer: evaluation of determinants of clinical outcome. Journal of clinical oncology 
: official journal of the American Society of Clinical Oncology 1988;6(9):1456-1466. 
33. 
Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM. A 
randomized phase 1 study of testosterone replacement for patients with low-risk 
castration-resistant prostate cancer. European urology 2009;56(1):97-103. 
34. 
Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, 
Schwartz LH, Scher HI. Phase 1 trial of high-dose exogenous testosterone in patients with 
castration-resistant metastatic prostate cancer. European urology 2009;56(2):237-244. 
35. 
Behre HM, Nieschlag E. Testosterone preparations for clinical use in males. In: 
Testosterone: Action,Deficiency. Cambridge University Press 2012;4th edition:309-335. 
36. 
Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, 
Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of 
bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: 
results from a pilot clinical study. Science translational medicine 2015;7(269):269ra262. 
37. 
Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Oral etoposide in the 
treatment of hormone-refractory prostate cancer. Cancer 1994;74(1):100-103. 
38. 
Teply BA, Kachhap S, Eisenberger MA, Denmeade SR. Extreme Response to High-dose 
Testosterone in BRCA2- and ATM-mutated Prostate Cancer. European urology 
2017;71(3):499. 
39. 
Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, 
Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, 
Carvajal R, Sengelov L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W. 
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic 
or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-
Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 2017;35(1):40-47. 
40. 
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, 
Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, 
Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, 
Gagnier P, Liu D, Gerritsen WR, Investigators CA. Ipilimumab versus placebo after 
radiotherapy in patients with metastatic castration-resistant prostate cancer that had 
progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-
blind, phase 3 trial. The lancet oncology 2014;15(7):700-712. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
74 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
41. 
McCarthy EF. CT-guided needle biopsies of bone and soft tissue tumors: a pathologist's 
perspective. Skeletal radiology 2007;36(3):181-182. 
42. 
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van 
Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the 
response to treatment in solid tumors. European Organization for Research and Treatment 
of Cancer, National Cancer Institute of the United States, National Cancer Institute of 
Canada. Journal of the National Cancer Institute 2000;92(3):205-216. 
43. 
Morris MJ, Scher HI, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, 
Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly 
WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small 
EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff 
PW, Armstrong AJ, Prostate Cancer Clinical Trials Working G. Trial Design and Objectives for 
Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer 
Clinical Trials Working Group 3. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology 2016;34(12):1402-1418. 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
75 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 
APPENDIX A: MANAGEMENT ALGORITHM FOR IMMUNO‐ONCOLOGY AGENTS 
 
 
These general guidelines constitute guidance to the Investigator. The guidance applies to all 
immuno-oncology agents and regimens. 
 
A general principle is that differential diagnoses should be diligently evaluated according to 
standard medical practice. Non-inflammatory etiologies should be considered and 
appropriately treated.  
 
Corticosteroids are a primary therapy for immuno-oncology drug-related adverse events. 
The oral equivalent of the recommended IV doses may be considered for ambulatory 
patients with low-grade toxicity. The lower bioavailability of oral corticosteroids should be 
taken into account when switching to the equivalent dose of oral corticosteroids. 
 
For subjects expected who require more than 4 weeks of corticosteroids or other 
immunosuppressants to manage an adverse event, consider the following 
recommendations: 
  
 
Antimicrobial/antifungal prophylaxis per institutional guidelines to prevent 
opportunistic infections such as Pneumocystis jiroveci (PJP) and fungal infections. 
 
 
Early consultation with an infectious disease specialist should be considered. 
Depending on the presentation, consultation with a pulmonologist for bronchoscopy 
or a gastroenterologist for endoscopy may also be appropriate. 
 
 
In patients who develop recurrent adverse events in the setting of ongoing or prior 
immunosuppressant use, an opportunistic infection should be considered in the 
differential diagnosis. 
 
 
Consultation with a medical or surgical specialist, especially prior to an invasive 
diagnostic or therapeutic procedure, is recommended. 
 
The frequency and severity of the related adverse events covered by these algorithms will 
depend on the immuno-oncology agent or regimen being used.

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
76 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
77 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
78 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
79 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
80 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
81 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
82 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
83 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
APPENDIX B: PERFORMANCE STATUS CRITERIA  
 
ECOG Performance Status Scale 
Karnofsky Performance Scale 
Grade 
Description 
% 
Description 
0 
Normal activity. Fully active, able to 
continue all predisease performance 
without restriction. 
100 
Normal, no complaints, no evidence 
of disease. 
90 
Able to carry on normal activity, 
minor signs or symptoms of disease. 
1 
Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity but ambulatory and able to 
carry out work of a light or sedentary 
nature (e.g. light housework, office 
work). 
80 
Normal activity with effort, some 
signs or symptoms of disease. 
70 
Cares for self, unable to carry on 
normal activity or to do active work. 
2 
In bed < 50% of the time. Ambulatory 
and capable of all self-care but unable 
to carry out any work activities. Up 
and about more than 50% of waking 
hours. 
60 
Requires occasional assistance but is 
able to care for most needs. 
50 
Requires considerable assistance and 
frequent medical care. 
3 
In bed > 50% of the time. Capable of 
only limited self-care, confined to bed 
or chair > 50% of waking hours. 
40 
Disabled, requires special care and 
assistance. 
30 
Severely disabled, hospitalization 
indicated. Death not imminent. 
4 
100% bedridden. Completely 
disabled, cannot carry on any self-
care, totally confined to bed or chair. 
20 
Very sick, hospitalization indicated. 
Death not imminent. 
10 
Moribund, fatal processes 
progressing rapidly. 
5 
Dead. 
0 
Dead. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
84 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
APPENDIX C: LABORATORY MANUAL 
 
Pathology will be reviewed and processed centrally at Johns Hopkins. Biopsy specimens 
will be handled and sampled in a uniform fashion. The lead pathologist at Johns Hopkins 
University, Dr. Angelo De Marzo, will perform the central review and prepare tissue for 
correlative analysis.   
 
For Outside Sites ONLY: Tumor tissue cores for FFPE will each be prepared into 
separate blocks (≥ 2 cores) and the cores for flash freezing will be combined into 1 
block (≥ 2 cores). Specimens will be sent for prior review to the De Marzo Laboratory 
on dry ice to the following address: 
 
De Marzo Laboratory 
Koch Cancer Research Building II 
1550 Orleans Street, Room 138 
Baltimore, Maryland 21231 
 
Please email a copy of the Tissue Sample Information Form (Appendix G) and the 
shipment tracking number to the Lead Site coordinator on the day of shipment. Be sure 
to include a copy inside of the shipping container. 
 
Tumor Tissue Specimens: 
 5 unstained slides and 1 H&E slide representative of tumor collected during the 
Screening period only, will be prepared and sent to Foundation Medicine for 
FoundationOne testing.  Tumor will be placed in the FoundationOne specimen kit 
and shipped to the following address by the De Marzo Laboratory: 
 
Foundation Medicine, Inc. 
7010 Kit Creek Road 
Morrisville, NC 27560 
Phone: 888.988.3639 
 
 20 unstained slides representative of tumor will be prepared from all collected 
biopsies and sent to the De Marzo Laboratory for PD-1, PD-L1, CD4, CD8, Ki-67, 
gamma-H2AX, 53BP1, and RAD51 analysis. 
 
 5 unstained slides representative of tumor will be prepared from all collected 
biopsies and banked in the De Marzo Laboratory for optional tissue banking to be 
utilized for future research. 
 
 
JHU Only: Page Tracy Jones (3-3186) for pick-up, processing, and transport of all tumor 
tissue to the De Marzo Laboratory. 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
85 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
MANAs/TAAs assay blood collection for JHU patients ONLY: 
1. Blood will be drawn into ten 10mL purple top (EDTA) tubes for a total volume of 
100mL for the MANAs/TAAs assay at C1D1, C4D1, and at progression (EOT). 
2. Tubes will be sent to the Johns Hopkins Immune Processing Core Lab for PBMC 
processing & plasma isolation for immune studies.  
3. Call the Immune Processing Core Lab (410-283-0693) for pick-up, processing, and 
transport. 
4. Once processing is complete, the Immune Processing Core Lab will contact Eugene 
Shenderov, MD and/or Mark Markowski, MD within 24-48 hours for transfer to 
long-term storage. 
 
Processing Instructions of MANAs/TAAs assay blood collection: 
1. Uncap purple tops and pour blood into 50mL conicals. 
2. Spin conicals at 2500rpm for 15min, 4°C, decel on 1. 
3. Collect plasma layer and immediately freeze in 2mL cryovials at -80°C; 1.5mL per 
vial. 
4. Dilute remaining blood 1 in 2 with PBS, gently mix up and down with a 10mL 
pipette. 
5. Allow blood to sit at room temperature on a rocker for ~30min to bring up 
temperature. 
6. Split diluted blood so there is ~35mL in each 50mL conical. 
7. Continue processing according to Leucosep protocol. 
8. Spin at 2200rpm for 20 minutes with accel and decel on “1” or off, depending on the 
centrifuge. 
9. Collect the buffy coat layer into 50mL conicals, ensuring no more than 20mL of buffy 
coat layer goes into each conical. 
10. Fill up remaining volume in the tubes with PBS. 
11. Spin at 1400rpm for 10min. 
12. Decant supernatant, break up pellet, and add 10mL PBS to each tube. 
13. Spin at 1000rpm for 10min. 
14. Assess the pellet. If there are a lot of RBCs, remove a few microliters and add 4mL 
ACK lysis buffer. 
15. Fill 50mL conical with PBS and spin for 5min at 1400rpm. 
16. Continue to decant off supernatant, break up pellet, and resuspend in 10mL PBS 
(30mL PBS for large blood draws or relevant volume depending on volume of blood 
received). 
17. Count cells, spin at 1400rpm for 5min, continue to decant off supernatant. 
18. Resuspend PBMC in pre-chilled AIM V media at a concentration of 10x106 cells/mL. 
19. Transfer 0.5mL aliquots (5x106 cells) to pre-labeled cryovials. Labels should contain 
patient lab ID, study number, time point, total number of cells, and date. 
20. Quickly add 0.5mL 10% AIM V to each vial and cap. Gently rotate upside down 
twice. 
21. Place in a slow freeze container at -80°C. Leave undisturbed overnight or for a 
minimum of 12 hours and a maximum of 24 hours. 
22. Transfer into liquid nitrogen for long-term storage. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
86 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
Chemokines Assay blood collection for JHU patients ONLY: 
1. Blood will be drawn into one 10mL EDTA purple top tube at C1D1 predose, 3 hours 
post BAT injection on C1D1, 3 days after the first BAT injection (C1D4), C2D1 predose, 
and C7D1 predose. 
2. Tubes should be sent to the Denmeade Laboratory for PBMC processing & plasma 
isolation for chemokine studies.  
3. Call Marc Rosen (410-502-3825/443-275-8982/410-502-8810) or Mark Markowski, 
MD for pickup when collection is complete. 
4. The Denmeade Laboratory will process the specimens and transport them to the 
Immune Processing Core Lab for analysis. 
 
Processing instructions of Chemokines assay: 
1. Uncap purple top tubes and transfer blood into 15mL conicals. 
2. Spin conicals at 2500rpm for 15min, 4°C, decel on “1”. 
3. Collect plasma layer and immediately freeze in 2mL cryovials at -80°C; 1mL per vial. 
 
Rectal swab collection for JHU patients ONLY: 
1. Rectal swabs will be collected via culture swab predose at C1D1, C4D1, and at C7D1. 
2. Culture swabs will be sent to the Sfanos Laboratory for processing. 
3. Call Sarah Ernst (443-386-8057) for pickup when collection is complete. 
 
Collection instructions of Rectal swab cultures: 
1. Write the subject ID, cycle visit, and the date and time of collection on the culture tubes 
for identification purposes. 
2. Gently insert each swab about 1.2 inches (3cm) into anus and swirl the swab in a 
circular motion for 15-30 seconds. 
3. Slowly remove each swab from anus without touching the skin and insert back into the 
tube. 
 
 
 
 
 
 
 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
87 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
APPENDIX D: GLOSSARY OF ABBREVIATIONS AND ACRONYMS 
 
17-AAG 
17-allylamino-17-demethoxygeldanamycin 
17-DMAG 
17-dimethylaminoethylamino-17-demethoxygeldanamycin 
2-MPPA 
2-(3-mercaptopropyl) Pentanedioic acid  
AdEERS 
Adverse Event Expedited Reporting System  
ADR 
Adverse drug reaction 
ADT 
Androgen-deprivation therapy 
AE 
Adverse event 
AGA 
Androgenetic alopecia 
AI 
Accumulation index 
ALT 
Alanine aminotransferase 
AML 
Acute myeloid leukemia 
ANC 
Absolute neutrophil count 
ANOVA 
Analysis of variance 
APTT 
Activated partial thromboplastin time 
AR 
Androgen receptor 
ASAEL 
Agent Specific Adverse Event List 
AST 
Aspartate aminotransferase 
AUC 
Area under the plasma concentration-time curve 
AUC(INF) 
Area under the concentration-time curve from time zero extrapolated to infinite 
time 
AUC(0-T) 
Area under the concentration-time curve from time zero to the time of the last 
quantifiable concentration 
AUC(TAU) 
Area under the concentration-time curve in one dosing interval 
AUMC(INF) 
Area under the moment concentration time curve extrapolated to infinity 
A-V 
Atrioventricular 
-HCG 
Beta-human chorionic gonadotrophin 
%BE 
Percent biliary excretion 
bid 
bis in die (twice a day) 
BLQ 
Below limit of quantification 
BMI 
Body mass index 
BP 
Blood pressure 
BSA 
Body Surface Area 
BUN 
Blood urea nitrogen 
C 
Celsius 
Ca++ 
Calcium 
caBIG 
Cancer Biomedical Informatics Grid 
CAEPR 
Comprehensive Adverse Event and Potential Risks 
CALGB 
Cancer and Leukemia Group B 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
88 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
CBC 
Complete blood count 
CCC 
Clinical Consortium Committee 
CCD 
Central Consortium Database 
CDE 
Common data element 
CDUS 
Clinical Data Update System  
CFR 
Code of Federal Regulations 
CI 
Confidence interval 
Cl- 
Chloride 
Clcr 
Creatinine clearance 
CLNR 
Nonrenal clearance 
CLR 
Renal clearance 
CLT 
Total body clearance 
CLT/F 
Apparent total body clearance 
Cm 
Centimeter 
Cmax 
Maximum plasma concentration 
Cmin 
Trough observed concentration 
COSTART 
Coding Symbols for Thesaurus of Adverse Reaction Terms 
CNS 
Central nervous system 
CR 
Complete response 
CRC 
Clinical Research Center 
CRDB 
Clinical Research Database 
CRF 
Case report form 
CRMIS 
Clinical Research Management Information System 
CRPC 
Castration resistant prostate cancer 
CT 
Computerized tomography 
CTC 
Circulating tumor cell 
CTCAE 
Common Terminology Criteria for Adverse Events 
CTEP 
Cancer Therapy Evaluation Program 
CTMS 
Clinical Trials Monitoring Service 
CTO 
Clinical Trials Office 
CV 
Coefficient of variation 
CYP 
Cytochrome p-450 
DCTD 
Division of Cancer Treatment and Diagnosis 
DEV 
Deviation from the nominal value 
%DEV 
Percent deviation 
dL 
Deciliter 
DHEA 
Dehydroepiandrosterone 
DHEA-S 
Dehydroepiandrosterone sulfate 
DHT 
Dihydrotestosterone 
DLT 
Dose-limiting toxicity 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
89 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
DSM 
Data and safety monitoring 
EA 
Extent of absorption 
ECG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
EDC 
Electronic data capture 
EEG 
Electroencephalogram 
EKG 
Electrocardiogram 
EORTC 
European Organization  for Research and Treatment of Cancer 
ESF 
Eligibility screening form 
ESR 
Expedited safety report 
F 
Bioavailability 
FDA 
Food and Drug Administration 
FDG-PET 
2-[18F]fluoro-2-deoxyglucose positron emitting tomography 
FDHT 
18-fluoro-dehydrotestosterone 
%FE 
percent fecal excretion 
FISH 
Fluorescence in situ hybridization 
FSH 
Follicle stimulating hormone 
GAPDH 
Glyseraldehayde-3-phophate dehydrogenase 
GC 
Gas chromatography 
GCP 
Good clinical practice 
GCPII 
Glutamate carboxypeptidase II enzyme 
GFR 
Glomerular filtration rate 
GGT 
Gamma-glutamyl transferase 
GnRH 
Gonadotropin-releasing hormone  
HAT 
Histone acetyltransferases 
HCO3- 
Bicarbonate 
HDAC 
Histone deacetylase 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
Human immunodeficiency virus 
HL7 
American National Standards Institute’s Health Level Seven 
HPF 
High power field 
HPLC 
High-performance liquid chromatography 
HR 
Heart rate 
HRPC 
Hormone-refractory prostate cancer 
HRT 
Hormone replacement therapy 
HSP90 
Heat-shock protein 90 
ICD 
International Classification of Diseases 
ICH 
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
IHC 
Immunochemical 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
90 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
IM 
Intramuscular 
IMSL 
International Mathematical Statistical Library 
IND 
Investigational new drug 
INR 
International normalized ratio 
IP 
Intraperitoneal 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat population 
IV 
Intravenous 
K 
Slope of the terminal phase of the log concentration-time curve 
K+ 
Potassium 
K3EDTA 
Potassium ethylenediaminetetraacetic acid 
KLK1 
Kallikrein 1 
LBD 
Ligand-binding domain 
LC 
Liquid chromatography 
LCM 
Laser capture microdissection 
LC-MS 
Liquid chromatography/mass spectrometry 
LD 
Longest diameter 
LDH 
Lactate dehydrogenase 
LLQ 
Lower limit of quantitation 
ln 
Natural logarithm 
LOCF 
Last observation carried forward 
LOI 
Letter of intent 
LPF 
Low power field 
MAD 
Maximum administered dose 
MDS 
Myelodysplasia 
MedDRA 
Medical Dictionary for Regulatory Activities 
MIC 
Minimum inhibitory concentration 
MMP 
Matrix metalloproteinase 
MRI 
Magnetic resonance imaging 
MRT 
Mean residence time 
MRT(INF) 
Mean residence time adjusted for infusion time 
MRT(PO) 
Mean residence time following oral administration 
MRT(SS) 
Mean residence time at steady-state 
MSKCC 
Memorial Sloan-Kettering Cancer Center 
MS 
Mass spectrometry 
MTD 
Maximum tolerated dose 
N 
Number of subjects or observations 
NA 
Not applicable 
N/A 
Not available 
NBN 
National Biospecimen Network 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
91 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
NCI 
National Cancer Institute 
NIH 
National Institutes of Health 
NOAEL 
No observed adverse effect level 
NOS 
Not otherwise specified 
NSAID 
Nonsteroidal anti-inflammatory drug 
NTX 
N-telopeptide cross-link 
NVB 
Neurovascular bundle 
OCR 
Office of Clinical Research at MSKCC 
PCCTC 
Prostate Cancer Clinical Trials Consortium 
PCRP 
Department of Defense Prostate Cancer Research Program 
PD 
Progressive disease 
PET 
Positron emission tomography 
PFS 
Progression-free survival 
PI 
Principal investigator 
PIN 
Prostatic intraepithelial neoplasia 
PK 
Pharmacokinetics 
PMB 
Pharmaceutical Management Branch 
PO 
per os (by mouth) 
PR 
Partial response 
PSA 
Prostate-specific antigen 
PSA-DT 
Prostate-specific antigen doubling time 
PSMA 
Prostate specific membrane antigen 
PT 
Prothrombin time 
PTT 
Partial thromboplastin time 
QC 
Quality control 
qd 
quaque die (every day) 
qRT-PCR 
Quantitative reverse transcription-polymerase chain reaction 
QOL 
Quality of life 
RBC 
Red blood cell 
RC 
Research Council 
RDBMS 
Relational Database Management System 
RDRC 
Radioactive Drug Research Committee 
RECIST 
Response Evaluation Criteria in Solid Tumors 
RP 
Radical prostatectomy  
RPC 
eResearch Program Coordinator 
RSA 
Research Study Assistant 
RSD 
Relative standard deviation 
%RSD 
Percent relative standard deviation 
SAE 
Serious adverse event 
SAHA 
Suberoylanilide hydroxamic acid 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
92 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
SC 
Subcutaneous 
SD 
Standard deviation 
SD 
Stable disease 
Seq 
Sequence 
SHBG 
Sex hormone binding globulin 
SKI 
Sloan-Kettering Institute for Cancer Research 
SMD 
Stable metabolic disease 
SOP 
Standard Operating Procedures 
SPORE 
Specialized Programs of Research Excellence 
STAR 
Symptom Tracking and Reporting 
SUV 
Standardized uptake value 
t 
Temperature 
t1/2 
Terminal half-life  
T 
Time 
TAUC(TAU) 
Trapezoidal area under the concentration-time curve in one dosing interval 
TAUC(0-T) 
Trapezoidal area under the concentration-time curve from time zero to the time of 
the last quantifiable concentration 
TDP 
Time to disease progression 
TGP 
Prostate-specific transglutaminase  
tid 
ter in die (3 times a day) 
TMA 
Tissue microarray  
Tmax 
Time of maximum observed concentration 
TMPRSS2 
Transmembrane protease, serine 2 
TNM 
Tissue, lymph node, metastases 
TX 
Treatment 
ULN 
Upper limit of normal 
ULQ 
Upper limit of quantitation 
UR 
Urinary recovery 
VEGF 
Vascular endothelial growth factor 
Vss 
Volume of distribution at steady-state 
WBC 
White blood cell 
WHO 
World Health Organization
 
 
 
 
 
 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
93 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
APPENDIX E: ACCEPTABLE BIRTH CONTROL METHODS 
 
Subjects with partners of childbearing potential, who are sexually active, must agree to the use of 
TWO highly effective forms of contraception (defined as a method that can achieve a failure rate of 
< 1% per year when used consistently and correctly) in combination [as listed below], throughout 
the period of taking study treatment and for at least 7 months after last dose of study drug(s), or 
they must totally/truly abstain from any form of sexual intercourse [see below].   
 
Highly Effective Non-hormonal birth control methods include: 
 
Total sexual abstinence. Abstinence must continue for the total duration of study treatment 
and for at least 1 month after the last dose. Periodic abstinence (e.g. calendar ovulation, 
symptothermal post ovulation methods) and withdrawal are not acceptable methods of 
contraception. 
 
Vasectomised sexual partner PLUS male condom. With participant assurance that partner 
received post-vasectomy confirmation of azospermia. 
 
Tubal occlusion PLUS male condom. 
 
IUD PLUS male condom. Provided coils are copper-banded. 
 
Highly Effective hormonal methods: 
 
Normal and low dose combined oral pills PLUS male condom. 
 
Cerazette (desogestrel) PLUS male condom. Cerazette is currently the only highly 
efficacious progesterone based pill. 
 
Hormonal shot or injection (e.g. Depo-Provera) PLUS male condom. 
 
Etonogestrel implants (e.g. Implanon, Norplant) PLUS male condom. 
 
Norelgestromin / EE transdermal system PLUS male condom. 
 
Intrauterine system [IUS] device (e.g. levonorgestrel releasing IUS - Mirena®) PLUS male 
condom. 
 
Intravaginal device (e.g. EE and etonogestrel) PLUS male condom. 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
94 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
APPENDIX F: ACTIONS REQUIRED IN CASES OF COMBINED INCREASE OF 
AMINOTRANSFERASE AND TOTAL BILIRUBIN – HY’S LAW 
 
1. 
INTRODUCTION 
 
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry. The investigator is responsible for determining whether a patient meets potential 
Hy’s Law (PHL) criteria at any point during the study. The Investigator participates, together with 
BMS clinical project representatives, in review and assessment of cases meeting PHL criteria to 
agree whether Hy’s Law (HL) criteria are met. HL criteria are met if there is no alternative 
explanation for the elevations in liver biochemistry other than Drug Induced Liver Injury (DILI) 
caused by the Investigational Medicinal Product (IMP). The Investigator is responsible for 
recording data pertaining to PHL/HL cases and for reporting Adverse Events (AE) and Serious 
Adverse Events (SAE) according to the outcome of the review and assessment in line with standard 
safety reporting processes. 
 
2. 
DEFINITIONS 
 
Potential Hy’s Law (PHL): 
 
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upper Limit of 
Normal (ULN) and Total Bilirubin (TBL) ≥ 2xULN at any point during the study irrespective 
of an increase in Alkaline Phosphatase (ALP).  
 
Hy’s Law (HL): 
 
AST or ALT ≥ 3xULN and TBL ≥ 2xULN, where no other reason, other than the IMP, can be 
found to explain the combination of increases, e.g. elevated ALP indicating cholestasis, viral 
hepatitis, another drug.  
 
3. 
IDENTIFICATION OF POTENTIAL HY’S LAW CASES 
 
In order to identify cases of PHL it is important to perform a comprehensive review of laboratory 
data for any patient who meets any of the following identification criteria in isolation or in 
combination: 
• ALT ≥ 3xULN 
• AST ≥ 3xULN 
• TBL ≥ 2xULN 
 
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will: 
• 
Determine whether the patient meets PHL criteria (see Section 2 of this Appendix for 
definition) by reviewing laboratory reports from all previous visits. 
• 
Promptly enter the laboratory data into the laboratory CRF. 
 
 
 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
95 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
4. 
FOLLOW‐UP 
 
Potential Hy’s Law Criteria not met 
If the patient does not meet PHL criteria the Investigator will: 
• 
Perform follow-up on subsequent laboratory results according to the guidance provided in 
the Clinical Study Protocol. 
 
Potential Hy’s Law Criteria met 
If the patient does meet PHL criteria the Investigator will: 
• 
Notify the BMS representative who will then inform the central Study Team. 
• 
The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study patients’ follow-up and the continuous review of data. Subsequent to 
this contact the Investigator will: 
 
Monitor the patient until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. 
 
Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the Study Physician. 
 
Complete the three Liver CRF Modules as information becomes available. 
 
If at any time (in consultation with the Study Physician) the PHL case meets serious 
criteria, report it as an SAE using standard reporting procedures. 
 
 
5. 
REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW CASES 
 
The instructions in this Section should be followed for all cases where PHL criteria are met.  No 
later than 3 weeks after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by the 
IMP. BMS and the Principal Investigator will also be involved in this review together with other 
subject matter experts as appropriate. According to the outcome of the review and assessment, the 
Investigator will follow the instructions below: 
 
If there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE: 
• 
If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF. 
• 
If the alternative explanation is an AE/SAE, record the AE/SAE in the CRF accordingly and 
follow BMS standard processes. 
 
If it is agreed that there is no explanation that would explain the ALT or AST and total bilirubin level 
elevations other than the IMP: 
• 
Report an SAE (report term ‘Hy’s Law’) according to BMS standard processes. 
 
The ‘Medically Important’ serious criterion should be used if no other serious 
criteria apply. 
 
As there is no alternative explanation for the HL case, a causality assessment of 
“related” should be assigned. 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
96 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
If, there is an unavoidable delay of over 3 weeks in obtaining the information necessary to assess 
whether or not the case meets the criteria for HL, then it is assumed that there is no alternative 
explanation until such time as an informed decision can be made: 
• 
Report an SAE (report term “Potential Hy’s Law”) applying serious criteria and causality 
assessment as per above. 
• 
Continue follow-up and review according to agreed plan. Once the necessary supplementary 
information is obtained, repeat the review and assessment to determine whether HL 
criteria are met. Update the SAE report according to the outcome of the review. 
 
 
6. 
ACTIONS REQUIRED FOR REPEAT EPISODES OF POTENTIAL HY’S LAW 
 
This section is applicable when a patient meets PHL criteria on study treatment and has 
already met PHL criteria at a previous on study treatment visit.   
 
The requirement to conduct follow-up, review and assessment of a repeat occurrence(s) of 
PHL is based on the nature of the alternative cause identified for the previous occurrence. 
The investigator should determine the cause for the previous occurrence of PHL criteria being 
met and answer the following question: 
 
• 
Was the alternative cause for the previous occurrence of PHL criteria being met chronic or 
progressing malignant disease? 
 
 
If No: follow the process described in Section 4 of this Appendix. 
 
If Yes: Determine if there has been a significant change in the patient’s condition# 
compared with when PHL criteria were previously met. 
 
If there is no significant change no action is required. 
 
If there is a significant change follow the process described in Section 4 of 
this Appendix. 
 
A “significant” change in the patient’s condition refers to a clinically relevant change in any of the 
individual liver biochemistry parameters (ALT, AST or total bilirubin) in isolation or in 
combination, or a clinically relevant change in associated symptoms. The determination of whether 
there has been a significant change will be at the discretion of the Investigator, this may be in 
consultation with the Study Physician if there is any uncertainty. 
 
 
7. 
REFERENCES 
 
FDA Guidance for Industry (issued July 2009) ‘Drug-induced liver injury: Premarketing clinical 
evaluation’: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U
CM174090.pdf 
 
 
 

Bipolar Androgen Therapy and Nivolumab in mCRPC 
IRB00164973 
Johns Hopkins University 
 
 
97 of 97 
COMBAT-CRPC Protocol Version 8.0 Date: June 9, 2021 
J1812 – COMbination of Bipolar Androgen Therapy and Nivolumab in Men with 
Metastatic Castration-Resistant Prostate Cancer [COMBAT-CRPC] 
Johns Hopkins University Multi-center Phase II Clinical Trial 
PI:  Mark Markowski, MD, Ph.D 
 
Appendix G: Tumor Sample Information Form 
 
Subject No.: ___________________________ 
     Site No.: ______________________ 
 
Study Visit:          Screening Period           Cycle 4 Day 1          Progression/EOT 
 
Date of Collection: ____________________ 
FFPE Tissue: 
 
No. of cores: _____________________ 
Consent obtained to allow storage of biospecimens for Future 
Research?             Yes                 No 
 
Flash Frozen Tissue:  
 
No. of cores: ______________________ 
 
 
Not applicable for site 
 
Label all cores and/or containers with the Fixative used (i.e. FFPE, Flash Frozen), 
Subject ID #, Cycle visit, & Date of collection. 
Shipping Address: 
De Marzo Laboratory 
Koch Cancer Research Building II 
1550 Orleans Street, Room 138 
Baltimore, MD 21231 
 
Please email a copy of this form and the shipment tracking number to the Lead Site 
coordinator on the day of shipment. Include a copy inside the shipping container.  
All tumor specimens should be shipped on dry ice.